Zaheer-Ud-Din Babar BPharm MPharm PhD SFHEA Professor in Medicines and Healthcare Director, Centre for Pharmaceutical Policy and Practice Research Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH United Kingdom https://research.hud.ac.uk/ourstaff/profile/index.php?staffid=1610
Editor-in-Chief, BMC Journal of Pharmaceutical Policy and Practice www.joppp.org
Trustee, Commonwealth Pharmacist Association (CPA), London, United Kingdom E-mail: [email protected] Phone (office): +441484471471 Mobile: +447850218953
Personal Details
Date of Birth: 2.4.74
Education Ph.D. (Pharmacy) Universiti Sains Malaysia, Penang, Malaysia (2003-2006) M. Pharm (Clinical Pharmacy) Universiti Sains Malaysia, Penang (1998-1999) B. Pharm. Bahauddin Zakarya University (BZU), Multan, Pakistan (1997)
Fellowship
Senior Fellow of the United Kingdom’s Higher Education Academy (SFHEA) 2019
Honorary Positions
Distinguished Professor, Institute of Medicines Safety, Xian Jiaotong University, Xian, China. September 2019
Distinguished Professor in Pharmaceutical Policy and Practice, Shandong University, China. April 2020
Distinctions/Awards
Zaheer-Ud-Din Babar, Ph.D. Page 2 of 50 2015 Wallath Prize (Top Prize) for Population Health Category (Summer studentship April 2015, University of Auckland, New Zealand). Todd Gammie, Lu, Y.C., Babar ZU. Examining global regulations and policies influencing access to orphan drugs: A systematic review of the literature (I have acted as a main supervisor/PI in this work)
2013 Second Prize for Population Health Category (Summer studentship April 2013, University of Auckland, New Zealand). Kilpatrik K, Vogler S, Babar ZU. Analysis of prices of medicines between New Zealand and Europe (I have acted as a main supervisor/PI in this work)
2012 Vice Chancellor’s Research Excellence Award in the Year 2012- University of Auckland, New Zealand
2009 Second Prize for Population Health Category (in Health X Conference Sep 2009, University of Auckland, New Zealand). Grover P, Babar ZU, Sheridan J, Bye L. General practitioners’ view regarding access to medicines in New Zealand (I have acted as a main supervisor/PI in this work)
2008 Sanggar Sanjung Award by Universiti Sains Malaysia (USM) for publishing highest impact factor paper (16.2) of 2007. Babar ZU, Ibrahim MIM, Singh H, Bukahri NI, Creese A (2007) Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia. PLoS Med 4(3): e82 doi:10.1371/journal.pmed.0040082
Professional Appointments Jan 2017- to date Professor in Medicines and Healthcare, Department of Pharmacy, School of Applied Sciences, University of Huddersfield, United Kingdom.
April 2018- to date Director, Pharmaceutical Policy and Practice Research Centre, School of Applied Sciences, University of Huddersfield, United Kingdom.
Feb 2016- Oct 2016 Dean and Professor, Lahore Pharmacy College Lahore, Pakistan
June 2011 to Dec 2015 Senior Lecturer and Head of Pharmacy Practice, School of Pharmacy, University of Auckland, New Zealand
Jan 2013 to Dec 2013 Examination Director, School of Pharmacy, University of Auckland, New Zealand
Zaheer-Ud-Din Babar, Ph.D. Page 3 of 50 Dec 2010 to June 2011 Senior Lecturer (Pharmacy Practice), School of Pharmacy, Faculty of Medical & Health Sciences, The University of Auckland, Auckland, New Zealand.
Dec 2007 to 10th Dec 2010 Lecturer (Pharmacy Practice), School of Pharmacy, Faculty of Medical & Health Sciences, The University of Auckland, Auckland, New Zealand.
Dec 2006 to Dec 2007 Lecturer, School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM), Penang, Malaysia.
July 2004-November 2006 Senior Lecturer, Clinical Pharmacy, School of Pharmacy, UCSI University Kuala Lumpur, Malaysia.
May 2000 - July 2004 Lecturer, School of Pharmacy, UCSI University Kuala Lumpur, Malaysia. Teaching in the areas of pharmacy practice, pharmacoeconomics, pharmacoepidemiology and clinical pharmacy.
Aug 1999 - April 2000 Staff Pharmacist, Dept. of Pharmacy Services, The Aga Khan University Hospital, Karachi, Pakistan.
Dec 1997- May 1998 Production Pharmacist, P.D.H. Pharmaceuticals (Pvt.) Ltd, Lahore, - Pakistan. involved in the areas of syrup manufacturing, tablet coating and sterile preparations.
Administrative Appointments
June 2011------Dec 2015 Member - School of Pharmacy’s, Admin Committee
Jan 2008------Dec 2013 Member, School of Pharmacy’s Research Committee
Jan 2013------Dec 2015 Examination Director, School of Pharmacy, UoA
Jan 2008 ---- Feb 2010 Coordinator -Pharma Tell Seminar Series, UoA
Jan 2008 ….. Feb 2010 Member of the School of Pharmacy’s Post Graduate Education Committee, UoA
July 2009- Dec 2009 Acting Chair “Pharmacy Practice Group”, UoA
March 2003- May 2003 Acting Head, School of Pharmacy, UCSI University Feb 2001-April 2001 Kuala Lumpur, Malaysia.
Zaheer-Ud-Din Babar, Ph.D. Page 4 of 50 2001 -2006 Advisor of the Pharmacy Student Association at the UCSI University, Kuala Lumpur, Malaysia.
2004 -2006 Member of the Student Disciplinary Board (SDB), UCSI University, Kuala Lumpur, Malaysia. Teaching Experience
Didactic
The University of Huddersfield
Jan 2017-current
Final Year (M. Pharm) SMP4002 SMP4001 Third Year (M.Pharm) SHP3003
MSc International Practice SMP0008 and Policy
The University of Auckland
December 2007-Dec 2015
Final Year (B. Pharmacy) Coordinator of Pharmacy 409 (Professional Pharmacy Studies) Pharmacy 410
Third Year (B.Pharmacy) Pharmacy 301
Second Year ( Pharmacy) Pharmacy 201
First Year (B. Pharmacy) Pharmacy 101
General Paper (Pharmacy) Pharmacy 111 G
Jan 2013-Dec 2015
Postgraduate courses Coordinator of Pharmacy 768-Innovative pharmacy services Pharmacy 767- Pharmacoeconomics Public Health-Population Health 715 Population Health 722 Pharmacy 700
Universiti Sains Malaysia, Penang, Malaysia Zaheer-Ud-Din Babar, Ph.D. Page 5 of 50
December 2006-December 2007
Fisrt Year (B.Pharmacy) Statistics for Pharmacy (FAR 151/4) Public Health Pharmacy (FAR 152/2)
Third Year (B. Pharmacy) Pharmaceutical Marketing (FEL 372/2)
Final Year (B.Pharmacy) Pharmacoeconomics Pharmacoepidemiology (FEL 471/2)
PhD in Clinical Pharmacy: Advanced Pharmacoeconomics Advanced Biostatistics
M Pharm(Clinical Pharmacy) Clinical Pharmacy Practice (FCP 554.4) Biostatistics and Study Design (FCP 556)
University College Sedaya International-Universiti Sains Malaysia Courses
May 2000-November 2006
Final Year: Introduction to Clinical Pharmacy Concept Clinical Pharmacy & Therapy Pharmacy Practice IV (Community Pharmacy Pharmacoepidemiology Pharmacoeconomics
Third Year: Cardiovascular System & Therapy (Clinical Pharmacy) Respiratory, Renal, Blood System & Therapy (Clinical Pharmacy) Central Nervous System and Therapy (Clinical Pharmacy) Pharmacy Practice III (Clinical Pharmacy) Gastrointenstinal System and Therapy (Clinical Pharmacy)
Second Year: Antimicrobial Therapy (Clinical Pharmacy) Endocrine System and Therapy (Clinical Pharmacy) Pharmacy Practice II Introduction to Traditional Medicine and Pharmacognosy
First Year: Pharmacy Practice I Statistics for Pharmacy (Research Methods) Communication Skills for Pharmacy Drugs in developing countries (Drug Policy Issues) Public Health Pharmacy Zaheer-Ud-Din Babar, Ph.D. Page 6 of 50
Curtin University of Technology, Australia – UCSI Courses
2003-2004 Epidemiology & Biostatistics (180)
University College Sedaya International (B.Pharmacy Programme)
2003-2006 Healthcare &Pharmacy (MP 181/2) Biostatistics for Pharmacy (MP 182/3)
“Dietitian Prescribing Course” (2011, University of Auckland) I have contributed in a special course, which is being designed for the Dieticians. It’s called “Dietitian Prescribing Course” and is being run and organized by the School of Pharmacy, University of Auckland. In this course, I have contributed a lecture on “PHARMAC, Pharmaceutical Schedule and Subsidy for Medicines and Special Foods” http://flexiblelearning.auckland.ac.nz/dietitian_prescribing/index.html
Lecturer and Speaker during Pharmacoeconomics Audio Conference Sep-No 2013 (NZ College of Pharmacists-University of Auckland)
During Sep-Nov 2013, I have acted as a presenter in a pharmacoeconomics module organised by the NZ college of Pharmacists. The module includes audio conferences and assignments. The participants in this course were NZ registered pharmacists
Research Experience
Visiting Researcher, Department of Population Medicine, Harvard Medical School, Harvard University, Boston MA.
During March/April 2014, I was the visiting researcher at Department of Population Medicine, Harvard Medical School, Harvard University, Boston, USA. During the visit the research linkages were established and key issues were explored in the areas of risk sharing schemes, coverage of health insurance and funding and access to high cost medicines
Visiting Researcher
2014-Sep, Health Action International, Amsterdam Netherlands
Supervision
University of Auckland (Dec 2007-Dec 2015) Zaheer-Ud-Din Babar, Ph.D. Page 7 of 50 University of Huddersfield (Jan 2017-till now)
Undergraduate Research Students No Year Students Status Topics Name 1 2008 Sharmin Started Nov Summer Studentship "Defining Clinical Pharmacy in Asia Nusrat 2008 Pacific" [Acted as main supervisor, co supervisor Prof John Completed Shaw] Feb 2009
2 2008 Pharmacy Started Feb Research Dissertation Course (Quality use of generic 2008, medicines in the Auckland Region: An evaluation of 410 Group Completed consumers, perceptions, attitudes and knowledge) [Acted as Oct 2008 main supervisor, co supervisor Ms Anne Rew] Project
3 2009 Pharmacy Started Feb Pharmacy 410- Research Dissertation Course (Evaluating 2009, Pharmacists and Prescribers Views and Perceptions 410 Group Completed regarding Generic Medicines in Auckland) [Acted as main in Oct 2009 supervisor, co supervisor Ms Anne Rew] Project
4 2008- Piyush Started Nov Summer studentship " Evaluating General Practitioners 2009 Grover 2008, regarding Access to Medicines in New Zealand" [Acted as completed main supervisor, co supervisors A/P Janie Sheridan and Ms Feb 2009) Lynne Bye] 5 2010 Pharmacy Started Feb Evaluating use of medicines in primary and secondary 2010, Parkinson disease at Middlemore Hospital [Acted as main 410 Group finishing in supervisor, co supervisors Shaheen Mannan& Dr Alka Garg] Oct 2010 Project 6 2010 Summer Started Nov Migrant Health in New Zealand: Exploring issues Concerning Student 2010- “Medicine Use and Access” [Acted as main supervisor, co Finished supervisor Prof John Shaw] (Kelly Feb 2011 Pengelly)
7 2011 Pharmacy Started Feb Optimising prescribing in primary healthcare: An evaluation 2011, of financial and clinical parameters 410 Group finishing in Oct 2011 [Acted as main supervisor, co supervisor,Keith Crump] Project Zaheer-Ud-Din Babar, Ph.D. Page 8 of 50 8 2011 Pharmacy Started Feb An evaluation of consumers ‘perceptions regarding private 2011, pharmaceutical insurance in Auckland 410 Group finished in Oct 2011 [Acted as main supervisor, co supervisor, Rajan Ragupathy] Project
9 2011- Hannah Yoo Started Nov Documenting and evaluating teaching and learning of 2012 2011, pharmacoeconomics: A systematic review of the finished in literature Feb 2012 [Acted as main supervisor]
10 2011- Shiu Wei Kan Started Nov Interventions promoting the uptake of generic medicines-A 2012 2011, systematic review of the literature finished in Feb 2012 [Acted as main supervisor]
11 2012 Pharmacy Started Feb Public perceptions regarding the role of Pharmaceutical 2012, Management Agency of New Zealand (PHARMAC) 410 Group finished in Oct 2012 [Acted as main supervisor] Project
12 2011- Pharmacy Started Feb Promoting Quality Use of Generic Medicines: Exploring and 2012 2012, Evaluating PHARMAC’s Pharmacist-Directed Interventions 410 Group finished in and Policies Oct 2012 [Acted as main supervisor] Project
13 2012 Kate Started Nov Analysis of prices of medicines in Europe and in New Zealand Kilpatrick 2012 – Finished March 2013
14 2013 Ali Abdul, Started Feb Access to subsidised medicines, cost of medicines and health Christine 2013- outcomes: Exploring general practitioners’ perceptions and Kim, James Finished experiences Mcintosh, Nov 2013 Malaika Samuel Namdas,Erica Zaheer-Ud-Din Babar, Ph.D. Page 9 of 50 Lourdes Rodrigues, Komal Vallabh
15 2015 Pharmacy Started Feb The future of pharmacy practice research: Assessing 410group 2015 academics and community pharmacists’ perceptions and Finished expectations Oct 2015
16 2014- Todd Started Nov Examining global regulations and policies influencing access 2015 Gammie 2014 – to orphan drugs: A systematic review of the literature Finished March 2015
17 2015- Ashna Starting: Direct to consumer advertising of prescription medicines: A 2016 Medina Siraj Nov 2015, systematic review of literature covering studies in US and NZ. Finished ( summer student) Feb 2016
18 2015- Eric Starting: Observational studies related to orphan drugs use and 2016 (Zhengyang) Nov 2015, outcomes: a systematic review of the literature Zhou Finished ( summer student) Feb 2016
19 2017- A.G.Royle- Started Comparison of service models of warfarin monitoring 2018 Pryor, September (Acted as a main supervisor, other supervisors are Syed Amina Brkic, 2017, Shahzad Hasan, Adam Yates, Wendy Sunter) Nadia Finished Ahmed, March 2018 Ramisha Ahmed 20 2017- Sonia Started Understanding the perceptions and beliefs of those 2018 Mahzamble, September suffering from diabetes among people of South Asian origin Claudia Beal, 2017, (Acted as a main supervisor, other supervisors are Syed Mohammad Finished Shahzad Hasan, Mahendra Patel, Sara Ramzan) Khan, Aysha March 2018 Khan
Zaheer-Ud-Din Babar, Ph.D. Page 10 of 50 Postgraduate Students
No Year Student’s Degree Status Topic Name 1 2008 Allan Wu MBE Started "Evaluating marketing opportunities of Feb. 2008, pharmaceutical pipeline products for in (Masters of completed licensing decisions: A case study of an Bioscience Dec 2008 Australian Pharmaceutical Company [Started as main supervisor, later as acted as co Enterprise) supervisor] 2 2007-2009 *Hind MSc Started " Impact of utilization and cost of health Mahjowb 2007 services among staff after policy changes in Abdallah Completed Universiti Sains Malaysia" [Acted as co- Ahmed March supervisor, main supervisor Prof Mohamed 2009) Izham Mohamed Ibrahim] (Universiti Sains Malaysia) 3 2008-2009 Ranya Hassan MSc Started "Evaluation of current inspection practices 2008 and development of best practices, models of Finished inspection of pharmaceutical facilities in Sep 2009) selected GCC countries". [Acted as co- supervisor, main supervisor A/P Sanjay Garg and Raida Alkasas] 4 2008 Michelle PhD Started An Evaluation of the Drug Development 2008- Industry in New Zealand - Innovations, Lockhart Completed Challenges and Opportunities [Acting as co- March supervisor , main supervisor A/P Sanjay 2012 Garg] 5 2008-2009 Gerallt Jones MSc Started An investigation of the use of complementary May 2008, and alternative medicine (CAM) among Completed children aged under 16 years with autism or March autistic spectrum disorder (ASD) in Aotearoa 2009) /New Zealand.) [Started as a co supervisor later acted as main Supervisor [with Associate Prof Joanne Barnes] 6 2007 *Shazia PhD Started Investigating perceptions of doctors, June 2007- pharmacists and consumers regarding quality Jamshed Completed use of generic medicines in Malaysia and June 2011 Pakistan [Acted as co supervisor, main supervisor Prof Mohamed Izham) at Universiti Sains Malaysia
7 2009 Alexandra Post Started Exploring the impact of the recent co- Plate Graduate May 2009 payment changes on consumers access to Diploma finished pharmacy services: a pharmacist’s Dec 2009 perspective
[Acted as co-supervisor, main supervisor Dr Fiona Kelly] Zaheer-Ud-Din Babar, Ph.D. Page 11 of 50
8 2009-2010 Jasmine Post (Status: Evaluating consumers perceptions regarding Neamat Allah Graduate Started Access to Medicines in New Zealand [Acted Diploma Nov 2009, as main supervisor] completed May 2010) 9 2010 Quincy Quink MSc Status: Access to medicines in NZ: Comparing the Che Liu Started health and economic indicators with the March United Kingdom, Australia and Canada 2010- [Acted as main supervisor] Finished Feb 2012 10 2009-2010 Oneal MA Status: Regional pooled procurement of essential Mendoza Started Dec medicines in the Western Pacific Region 2008 Acted as co-supervisor Finished Jan 2010
11 2010 Philip Post Started Access to high cost medicines [Acted as main Wahlster Graduate Nov 2010- supervisor] Diploma Finished April 2011
12 2010 Munazza MPhil Started The impact of therapy of interferons on the Tanveer Nov 2008- economic and clinical outcome in patients Finished with chronic hepatitis c in Pakistan Dec 2011 (Acted as co-supervisor)
13 2012 Mohammad PhD Started Jan Medicines pricing availability and Bashaar 2012- affordability in Afghanistan finished Dec 2015 (The student is registered at USM, Malaysia, I am acting as co-supervisor)
14 2012 Syed Zia PhD Started The impact of irrational prescription of Husnain Jan2012 – medicines on health outcomes [Acted as cosupervisor] 15 2015 Raveena Visiting Started: The future of pharmacy practice research: Nagaria student July 2015, what academics and practitioners want! Finished (King’s Nov 2015 College [Acted as main supervisor] London) Zaheer-Ud-Din Babar, Ph.D. Page 12 of 50 16 2015 Rozina Visiting PhD Started Medicines management and pharmaceutical Kousar student June 2015, care: a systematic review of the literature Finished December [Acted as main supervisor in Auckland] 2015 17 2015 Piyush MBBS with Started Exploring the extent and scope of medicines Grover Honours at March access programmes to cancer medicines in The 2015, Australia and NZ. University Finished of Notre Sep 2015 Acted as co-supervisor. The other Dame supervisors are Dr. Raoul Oehmen, Dr Agnes Australia Vitry
18 2015 Angelica de Masters Started The impact of the Trans-Pacific Partnership Guzman student April 2015, on Access and Prices of Biosimilars in NZ Finished Acted as co supervisor. The other supervisor Nov 2015 is Dr. Pat Neuwelt
19 2016 Furqan PhD student Started Impact of pharmacists’ intervention on Hashmi April 2016, pharmacy services Finished August Acted as co-supervisor 2017
20 2017 Tsitsi Grace PhD student 2014- Evaluation of NQO1 as a Risk Factor and Chituku Finished Potential Target for Cervical Cancer 2018 Acted as co-supervisor
21 2017 Sara Ramzan PhD student Started Evaluating impact and health outcomes of June 2017 newer antidiabetics Acting as a main supervisor
22 2017 Kamran PhD student Started July Extended pharmacy services in Saudi Arabia Rasheed 2017 Acting as a main supervisor
23 2017 Maimuna MSc Started Diabetes patients’ experiences with Rasheed (Danish Nov 2017 pharmacists’ counselling in Nelson, England School of Completed Pharmacy Dec 2018 Copenhagen Student) 24 2018 Saima Afzal PhD student Started Evaluating impact and health outcomes of April 2018 newer anticoagulants Acting as a main supervisor
25 2018 Nasir Abbas PhD student Started Sep Reimbursement and medicines funding 2018 policies in UK Zaheer-Ud-Din Babar, Ph.D. Page 13 of 50 Acting as a main supervisor
26 2018 Raveena PhD student Started Sep Evaluating pharmaceuticals and public policy Nagaria 2018 Acting as a co- supervisor
27 2018 Noshad MSc Started Sep GP practice pharmacists and prescribing Akhtar Student 2018 practices in Australia, and the UK Submitted Acting as a main supervisor Finished August 2020 28 2019 Amie Bain PhD student Started Jan Evaluating insulin prescribing patterns in 2019 secondary care in UK Acting as a main supervisor
29 2019 Nadeem Zia MSc Started Jan Identifying priority medicines policy issues Student 2019 in Qatar Acting as a main supervisor
30 2019 Saba Shamim MSc Started Jan Pharmacists continuing professional Student 2019 development in selected commonwealth Submitted countries thesis May Acting as a main supervisor 2020 31 2019 Phyllis Ocran PhD student Started Jan Cancer medicines pricing and accessibility in 2019 selected countries in Africa Acting as a main supervisor
32 2019 Ahmer Mirza PhD Started Priority medicines policy issues in Saudi Student April 2019 Arabia Acting as a main supervisor
*I acted as a supervisor for Shazia and Hind while I was working at the University Sains Malaysia (USM) in 2007. In early 2008, I was appointed field supervisor/co supervisor for both students by USM (Official letter is available upon request) Previous Supervision of MSc/PhD students (at University Sains Malaysia, Penang and UCSI University, Kuala Lumpur) 2007- Saira Azhar, PhD Student [Evaluating role of Pharmacists in Public health in Pakistan] 2007- Imran Masood, PhD Student [Evaluating promotional practices of pharmaceutical industry in Pakistan and Malaysia] 2007- Syed Shahzad Hassan, MSc Student [Anti-epileptic drug utilization and seizure outcome among paediatric patients in a Malaysian Public Hospital] 2007- Ali Saleh Alkhoshaiban, MSc [Evaluating Prescribing Practices & Cost of illness of Peptic Ulcer Disease] 2006- Daphne Chan, Honours Student [With University of South Australia, Prescribing habits of dispensing doctors in Malaysia – focusing on hypertension] Zaheer-Ud-Din Babar, Ph.D. Page 14 of 50
Clinical Precepting
University College Sedaya International- Hospital Kuala Lumpur
May2003-November2006 Clinical pharmacy preceptor in the areas of pediatrics, surgery, medicine, in patient services, outpatient pharmacy services and hospital pharmacy management.
Universiti Sains Malaysia December 2006-present Surgery
Editor –in- Chief Journal of Pharmaceutical Policy and Practice (Formerly known as Southern Med Review) In December 2008, I started Southern Med Review to promote pharmaceutical policy research at a global level. Southern Med Review was a biannual peer reviewed scientific journal.The journal has been unique in publishing the work of new researchers, documenting the pharmaceutical situation of low-and middle-income countries and debating pertinent pharmaceutical policy questions. The journal also published studies on the pharmaceutical situation of countries where little or no pharmaceutical literature was available e.g. Slovenia, Macedonia and Afghanistan. Moreover, the published studies have been instrumental in changing medicines policies in certain regions, especially in Vietnam and Thailand. The journal is indexed in PubMed, Scopus, and inWHO’s Essential Medicines Documentation Database. http://www.ncbi.nlm.nih.gov/pmc/journals/1901/ http://www.ncbi.nlm.nih.gov/pmc/journals/1901/
As the Chief Editor of the Journal, I have edited the following issues:
• Vol I Issue 1 Dec 2008
• Vol 2 Issue 1 April 2009 and Vol 2 Issue 2 Sep 2009
• Vol 3 Issue 1 Feb 2010 and Vol3 Issue 2 October 2010
• Vol 4 Issue 1 April 2011 and Vol 4 Issue 2 Dec 2011
• Vol 5 Issue 1 July 2012 and Vol 5 Issue 2 Dec 2012
Because of the Journal’s success and its niche in global pharmaceutical policy, BioMed Central, a UK based publisher has relaunched the journal as Journal of Pharmaceutical Policy and Practice in 2013. https://joppp.biomedcentral.com/
Zaheer-Ud-Din Babar, Ph.D. Page 15 of 50
Publications
1. Rong, X., Yin, J., Duan, S., Sun, Q., Babar, Z.U.D. (2020) The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis. BMC Public Health 20:588 2. Alves da Costa, F., Henman, M., Hughes, C., Leufkens, H., Babar, Z-U-D., McElnay, J., & Schulz, M. (2020). Impact of a global leader on pharmaceutical practice and policy around the world. Journal of Pharmaceutical Policy and Practice, 13, [51]. https://joppp.biomedcentral.com/track/pdf/10.1186/s40545-020-00253-z 3. Dawoud, D. M., Chen, A., Rossing, C., Garcia-Cardenas, V., Law, A., Aslani, P., Bates, I., Babar, Z-U-D., & Desselle, S. (2020). Pharmacy practice research priorities during the COVID-19 pandemic: Recommendations of a panel of experts convened by FIP Pharmacy Practice Research Special Interest Group. Research in Social and Administrative Pharmacy. https://doi.org/10.1016/j.sapharm.2020.08.020
4. Bain, S.S. Hasan, S. Kavanagh, Z.‐U.‐D. Babar. (2020) Use and validation of a survey tool to measure the perceived effectiveness of insulin‐prescribing safety interventions in UK hospitals. Diabetic Medicine 26 June https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14351 5. Halimi, V.; Daci, A.; Ancevska Netkovska, K.; Suturkova, L.; Babar, Z.-U.-D.; Grozdanova, A. (2020) Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. Int. J. Environ. Res. Public Health 2020, 17, 5800. 6. Hussain R, Dawoud DM, Babar ZU.(2020) Drive-thru pharmacy services: A way forward to combat COVID-19 pandemic [published online ahead of print, 2020 Jul 22]. Res Social Adm Pharm. 2020;S1551-7411(20)30601-X. doi:10.1016/j.sapharm.2020.07.015 7. Atif M, Fatima R, Ahmad N, Babar ZU (2020). Treatment outcomes of extrapulmonary tuberculosis in Bahawalpur, Pakistan; a record review. J Pharm Policy Pract. 2020;13:35. Published 2020 Jul 24. doi:10.1186/s40545-020-00227-1
8. Hafner, T., Banda, M., Kohler, J., Babar, Z., Lumpkin, M., Adeyeye, M. C., Nfor, E., Aboagye-Nyame, F., Guzman, J. (2020). Integrating pharmaceutical systems strengthening in the current global health scenario: three ‘uncomfortable truths’. Journal of Pharmaceutical Policy and Practice, 13, 38. https://doi.org/10.1186/s40545-020-00242-2
9. El-Dahiyat, F., Rashrash, M., Abuhamdah, S., Abu Farha, R., Babar, Z-U- D. (2020) Herbal medicines: a cross-sectional study to evaluate the prevalence and predictors of use among Jordanian adults. Journal of Pharmaceutical Policy and Practice. : 13, 1, 9 p., 2.
10. Hussain, R., Hassali, M. A., Rehman, A., Muneswarao, J., Atif, M., Babar, Z.-U.-D. (2020) A qualitative evaluation of adverse drug reaction reporting system in. Pakistan: Findings from the nurses’ perspective. Int. J. Environ. Res. Public Health (In Press) Zaheer-Ud-Din Babar, Ph.D. Page 16 of 50 11. Bukhari, N., Rasheed, H., Nayyer, B., Babar, Z-U-D. (2020) Pharmacists at the frontline beating the COVID-19 pandemic. Journal of Pharmaceutical Policy and Practice. : 13, 8 . https://doi.org/10.1186/s40545-020-00210-w
12. Babar, Z.U.D. (2020) The Need for an Evidence-Based Encyclopaedia in Health Services Research in Pharmacy. Int. J. Environ. Res. Public Health 2020, 17(7), 2549; https://doi.org/10.3390/ijerph17072549 13. Atif, M.; Razzaq, W.; Mushtaq, I.; Malik, I.; Razzaq, M.; Scahill, S.; Babar, Z.-U.-D. (2020) Pharmacy Services beyond the Basics: A Qualitative Study to Explore Perspectives of Pharmacists towards Basic and Enhanced Pharmacy Services in Pakistan. Int. J. Environ. Res. Public Health 17, 2379. 14. Chan, A.H.Y., Rutter, V., Ashiru-Oredope, D., Tuck,C., Babar, Z.-U.-D. (2020) Together we unite: the role of the Commonwealth in achieving universal health coverage through pharmaceutical care amidst the COVID-19 pandemic. J of Pharm Policy and Pract 13, 13 . https://doi.org/10.1186/s40545-020-00214-6 15. Bukhari, N., Maanzoor, M., Rasheed, H., Nayyer, B., Malik, M., Babar, Z-U-D. (2020) A step towards gender equity to strengthen the pharmaceutical workforce during COVID-19. J of Pharm Policy and Pract 13, 15 https://doi.org/10.1186/s40545-020- 00215-5 16. Omer, S., Ali, S., Babar, Z.D. (2020) Preventive measures and management of COVID-19 in pregnancy. Drugs Ther Perspect https://doi.org/10.1007/s40267-020- 00725-x 17. Zarei, L., Karimzadeh, I., Moradi, N., Peymani, P., Asadi, S., Babar, Z.U.D (2020) Affordability assessment from a static to dynamic concept: A scenario-based assessment of Cardiovascular Medicines. International Journal of Environmental Research and Public Health. 17, 1710. 18. Nirwan, J.S., Hasan, S.S., Babar, Z. Conway, R, B., Ghori, M.U. (2020) Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep 10, 5814 . https://doi.org/10.1038/s41598-020-62795-1 19. S. S. Hasan., S. H. Chang., K. Thiruchelvam., D. W. K. Chong., Z. U. Babar (2020) Drug burden index, polypharmacy and patient health outcomes in cognitively intact older residents of aged care facilities in Malaysia. Journal of Pharmacy Practice and Research (In Press) 20. Dawoud, D., El-Dahiyat, F., Abojedi , A., Dawoud , N., Ahmed, M, S., Hussein, M., Mohamed, O., Hasan, S.S., Babar, Z.U.D., Kharroubi, S.A. (2020) Translation, Cultural Adaptation and Psychometric Validation of the SF-6D Measure of Health-related Quality of Life for Use in Arabic-Speaking Countries. Research in Social and Administrative Pharmacy (In Press) 21. Bain, A., Kavanagh, S., McCarthy, S. Babar, Z-U-D. (2019) Assessment of Insulin- related Knowledge among Healthcare Professionals in a Large Teaching Hospital in the United Kingdom. Pharmacy. 7, 1, 9 p. 2019
22. Abdel Rida, N., Mohamed Ibrahim, M.I., Babar, Z.U.D. (2019) Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon. BMC Health Services Research, Vol 19, Article Number 973 (In Press)
Zaheer-Ud-Din Babar, Ph.D. Page 17 of 50 23. Bain, A., Hasan, S., Babar, Z.-U.-D. (2019) Strategies to reduce insulin prescribing errors in UK hospitals: Results from a national survey. Diabetic Medicine (in Press) 24. Abbas N, Hasan SS, Curley L, Babar ZU. Access to medicines - a systematic review of the literature [published online ahead of print, 2019 Dec 11]. Res Social Adm Pharm. 2019;S1551-7411(19)30647-3. doi:10.1016/j.sapharm.2019.12.009 25. Babar, Z-U-D., Ramzan, S., El-Dahiyat, F., Tachmazidis, I., Adebisi, A. & Hasan, S.S.,(2019) The Availability, Pricing and Affordability of Essential Diabetes Medicines in 17 Low-, Middle- and High-Income Countries Frontiers in Pharmacology. 10, 10 p., 1375. 26. Mirza, A. H., Hasan, S. S., El-Dahiyat, F. & Babar, Z. U. D., (2019) Medicines policies issues for Saudi Arabia: Priorities and models: Journal of Pharmaceutical Health Services Research 10, 4, p. 443-445 3 p.
27. Nagaria, R. A., Hasan, S. S. & Babar, Z. U. D., (2019) Pharmacy, pharmaceuticals and public policy: Solving the puzzle Research in Social and Administrative Pharmacy. (In Press)
28. Hasan, S. S., Zaidi, S. T. R., Nirwan, J., Ghori, M. U., Javid, F., Ahmadi, K. & Babar, Z-U- D., (2019): Use of Central Nervous System (CNS) Medicines in Aged Care Homes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 8, 9, 17 p.
29. Baines, D., Nørgaard, LS., Babar, ZUD., Rossing, C. (2019) The Fourth Industrial Revolution: Will it change pharmacy practice? Research in Social and Administrative Pharmacy https://doi.org/10.1016/j.sapharm.2019.04.003
30. Asghar, S., Atif, M., Mushtaq, I., Malik, I., Hayat, K. & Babar, Z. U. D.( 2019) Factors associated with inappropriate dispensing of antibiotics among non-pharmacist pharmacy workers In : Research in Social and Administrative Pharmacy. 10.1016/j.sapharm.2019.09.003
31. Kasonde, L., Tordrup, D., Naheed, A., Zeng, W., Ahmed, S. & Babar, Z-U-D., (2019) Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology.: BMC Health Services Research. 19, 1, p. 1-12 12 p., 383.
32. Rasheed MK, Hasan SS, Babar ZU, Ahmed SI. Extensively drug-resistant typhoid fever in Pakistan. The Lancet Infectious Diseases. 2019;19(3): 242-243
33. Abdel Rida, N., Mohamed Ibrahim, M. I. & Babar, Z-U-D. (2019) Pharmaceutical pricing policies in Qatar and Lebanon: narrative review and document analysis. Journal of Pharmaceutical Health Services Research. 10, 3, p. 277-287 11 p.
34. Ramzan, S., Timmins, P., Hasan, S. S. & Babar, Z-U-D. (2019) Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000–2018 Primary Care Diabetes. 13, 5, p. 409-421 13 p.
Zaheer-Ud-Din Babar, Ph.D. Page 18 of 50
35. Husnain, Z., Bukhari, NI., Hussain, K, Babar, Z-U-D., Salman, Hashmi, FK., Saleem, Z., M., Curley L (2019) Cross verification of prescribing trends through loop evaluation of physicians, patients and medical store personnel. BMC Health Services Research 19, 1, p. 1-10 10 p., 328.
36. Babar ZU, Gammie T, Seyfoddin A, Hasan SS, Curley, LE (2018). Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review. Research in Social and Administrative Pharmacy, 15(3), 231-243.
37. Bain, A., Hasan, S., Babar, Z.-U.-D. (2019) Interventions to improve insulin prescribing practice for people with diabetes in hospital: A systematic review Diabetic Medicine) 36, 8, p. 948-960 13 p.
38. Atif M, Asghar S, Mushtaq I, Malik I, Amin A, Babar ZU, Scahill S. (2019)What drives inappropriate use of antibiotics? A mixed methods study from Bahawalpur, Pakistan. Infection and Drug Resistance, 2019, 12, 687-699
39. Afzal, S.K., Hasan, S.S., Babar, Z. U. (2019)A Systematic Review of Patient Reported Outcomes Associated with the Use of Direct-acting Oral Anticoagulants, British Journal of Clinical Pharmacology (In Press)
40. Saeed, A., Saeed, H., Saleem, Z., Fang, Y. & Babar, Z-U-D.(2019) Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology PLoS One. 14, 4, 16 p., e0216122.
41. Babar ZU, Kousar R, Hasan SS, Scahill S, Curley LE. Glycemic control through pharmaceutical care: a meta‐analysis of randomized controlled trials. Journal of Pharmaceutical Health Services Research, 2019, 10 (1), 35-44
42. Ramzan S, Timmins P, Hasan SS, Babar ZU. Cost analysis of type 2 diabetes mellitus treatment in economically developed countries. Expert review of pharmacoeconomics & outcomes research, 2019, 19 (1), 5-14 43. Ali S, Egunsola O, Babar ZU, Hasan SS. Challenges of conducting clinical trials in Asia. 08/2018; 5(4)., DOI:10.18203/2349-3259.ijct20183748
44. Ali S, Egunsola O, Babar ZU, Hasan SS. Clinical trials in Asia: A World Health Organization database study. Perspectives in clinical research 08/2018; 10(4)., DOI:10.4103/picr.PICR_109_18
45. Babar ZU, Conway BR. Huddersfield opens new centre for pharmacy policy and practice research. Pharmaceutical Journal 05/2018; DOI:10.1211/pj.2018.20204883 Zaheer-Ud-Din Babar, Ph.D. Page 19 of 50 46. Babar ZU. The need for a new science, technology and medicine University in the Middle East: Carving the future. F1000 Research 04/2018; 7., DOI:10.12688/f1000research.14600.1
47. Robertson, D. L. N. & Babar, Z. U. D. (2018) Pharmaceutical Care of Patients with Cancer Treated on Non-Cancer Wards in the UK: A Mixed Methods Study.: European Journal of Hospital Pharmacy. 11/2018; DOI:10.1136/ejhpharm-2018-001662
48. Tuck C, Maamri, A., Chan AHY, Babar ZUD (2018) Medicines pricing, access and safety in Morocco. Tropical Medicine and International Health https://doi.org/10.1111/tmi.13191. (In Press) 49. Hasan, S. S., Kow, C. S., Dawoud, D., Mohamed, O., Baines, D. & Babar, Z. U. D. (2018) Pharmaceutical Policy Reforms to Regulate Drug Prices in Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea. Value in Health Regional Issues. 18, p. 18-23 6 p. 50. Hasan, S. S., Sunter, W., Ahmed, N., Royle-Pryor, A., Brkic, A., Ahmed, R., Afzal, S. & Babar, Z. U. D. (2018) A Comparison of Warfarin Monitoring Service Models. Research in Social and Administrative Pharmacy. 15, 10, p. 1236-1242 7 p.
51. El-Dahiyat, F., Curley, L. E. & Babar, Z. U. D. (2018) A Survey Study to Measure the Practice of Patient Counselling and Other Community Pharmacy Services in Jordan: Journal of Pharmaceutical Health Services Research. 10, 1, p. 133-139 7 p.
52. Atif, M., Saleem, Q., Babar, Z. U. D. & Scahill, S. (2018) Association Between the Vicious Cycle of Diabetes-Associated Complications and Glycemic Control Among the Elderly: A Systematic Review: Medicina (Kaunas, Lithuania). 54, 5, 24 p. 53. Rasheed, K., Hasan, SS., Babar ZU (2018). Community pharmacist’s knowledge, attitude, roles and practices towards patient-centered care in Saudi Arabia: A systematic review of the literature. Journal of Pharmaceutical Health Services Research 10(1):101-115
54. Hasan SS, Chiew ACH, Chong DWK, Babar ZU (2018).,Associations Between Drug Burden Index, Medication Appropriateness and Patient-Reported Outcomes in the Community Pharmacy Setting in Malaysia.: Drugs and Therapy Perspectives. 34, 9, p. 437-443 7 p.
55. Eljilany I, El-Dahiyat F, Curley LE, Babar ZU (2018). Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries. Expert Rev Pharmacoecnomics & Outcomes Res. May 19. doi: 10.1080/14737167.2018.1479254
56. Baines D, Ghair IK., Hussain, A., Khan, AJ., Schneider, P., Hasan SS, Babar ZU (2018). A scoping review of the quality and the design of evaluations of mobile health. Front. Pharmacol. | doi: 10.3389/fphar.2018.00678
Zaheer-Ud-Din Babar, Ph.D. Page 20 of 50 57. Hasan SS, Kow CS, Baines D, Babar ZU (2018). Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults. Expert Review of Pharmacoeconomics and Outcomes Research, May 9:1-7.
58. Thiruchelvam, K., Wong P.S., Kairuz, T., Babar, Z.U.D, Hasan, S.S. (2018). Consolidated Medication Review Algorithm to Improve Medications Use in Older Adults. Components, Scoring Scheme, and Implementation.Journal of the American Medical Directors Association (JAMDA) . 19, 8, p. 717-718 2 p
59. Rutter, V., Chan, A. H. Y., Tuck, C., Bader, L., Babar, Z-U-D., & Bates, I. (2018). Weaving the health and pharmaceutical care agenda through the themes of the commonwealth heads of government meeting (CHOGM), London 2018. Journal of Pharmaceutical Policy and Practice, 11, [10]. DOI: 10.1186/s40545-018-0140-3
60. Nguyen, T. A., Babar, Z.U.D. (2018). Use of potentially inappropriate medications in people with dementia in Vietnam and its associated factors. American Journal of Alzheimer's Disease and Other Dementias, https://doi.org/10.1177/1533317518768999
61. Husnain, SZ., Bukhari, NI., Hussain, K., Babar, ZUD., Saleem, Z (2018). Inappropriateness of medication use and associated health risks: A cross-sectional study from Pakistan. Tropical Journal of Pharmaceutical Research April 2018; 17 (4): 715-721
62. Hashmi, F.K., Hassali, M.A., Saleem, F., Babar, Z.U.D, Ahmad, A., Khan, M.U. A (2018). qualitative study exploring perceptions of policymakers about community pharmacy practice and extended pharmacy services in Lahore, Pakistan. Journal of Pharmaceutical Health Services Research, 9(1):71-73 doi: 10.1111/jphs.12216 63. Babar, Z.U.D., Scahill, S., Nagaria, R., Curley, L. (2018) The future of pharmacy practice research – Perspectives of academics and practitioners from Australia, NZ, United Kingdom, Canada and USA. Research in Social and Administrative Pharmacy 14, 12, p. 1163-1171 9 p.
64. Shah, T.K., Tariq, T., Phillips, R., Davison, S., Hoare, A., Hasan, S.S., Babar, Z.U.D (2018) Health care for all: effective, community supported, healthcare with innovative use of telemedicine. Journal of Pharmaceutical Policy and Practice. Feb 1;11:3 doi: 10.1186/s40545-018-0130-5
65. Salmasi, S., Lee, K.S., Ming, L.C., Neoh, C.F., Elrggal, M.E., Babar, Z.U., Khan, MU., Hadi, M.A. (2017) Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region. BMC Cancer 17:903 https://doi.org/10.1186/s12885-017-3888-y
66. Scahill, S., Atif, M., Babar, Z.U.D. (2017) Defining pharmacy and its practice: a conceptual model for an international audience. Integrated Pharmacy Research and Practice 2017:6 121–129
Zaheer-Ud-Din Babar, Ph.D. Page 21 of 50 67. Atif, M., Scahill, S., Azeem, M., Sarwar, M. and Babar, Z. (2017) ‘Drug utilization patterns in the global context: A systematic review’ Health Policy and Technology . ISSN 2211-8837 68. Grover, P., Babar, Z.U.D., Oehman, R., Vitry, A (2017). Medicines Access Programs to cancer medicines in Australia and New Zealand: An exploratory study. Health Policy Available online 20th December http://dx.doi.org/10.1016/j.healthpol.2017.12.004 69. Hassan, S., Thiruchelvam, K., Kow, C., Ghori, M. and Babar, Z. (2017) ‘Economic evaluation of pharmacist-led medication reviews in residential aged care facilities’ Expert Review of Pharmacoeconomics & Outcomes Research , 17 (5), pp. 431-439. ISSN 1473-7167 70. Baines, D. and Babar, Z. (2017) Baines and Babar: Why medical practitioners should be interested in the World Bank Available at: http://blogs.bmj.com/bmj/2017/08/31/baines-and-babar-why-medical- practitioners-should-be-interested-in-the-world-bank/ 71. Bain, A., Nettleship, L., Kavanagh, S. and Babar, Z. (2017) ‘Evaluating insulin information provided on discharge summaries in a secondary care hospital in the United Kingdom’ Journal of Pharmaceutical Policy and Practice , 10 (1). ISSN 2052- 3211 72. Abdel Rida, N., Mohamed Ibrahim, M., Babar, Z. and Owusu, Y. (2017) ‘A systematic review of pharmaceutical pricing policies in developing countries’ Journal of Pharmaceutical Health Services Research . ISSN 1759-8885
73. Vogler, S., Paris, V, Ferrario, A., Wirtz, VJ., Joncheere, KD., Peter Schneider, Pedersen, HB., Dedet, G., Babar, Z.U.D (2017) How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Applied Health Economics and Health Policy. doi:10.1007/s40258-016- 0300-zhttp://link.springer.com/article/10.1007%2Fs40258-016-0300-z
74. Sarwar, M., Atif, M., Scahill, S., Saqib, A., Qamar-uz-Zaman, M. and Babar, Z. (2017) ‘Drug utilization patterns among elderly hospitalized patients on poly-pharmacy in Punjab, Pakistan’ Journal of Pharmaceutical Policy and Practice , 10 (1). ISSN 2052- 3211
75. Saleem, A., Khan, A., Ahmad, A., Khan, M. and Babar, Z. (2017) ‘Patient inaccessibility to antifungal drugs in developing nations: The case of Pakistan’ Research in Social and Administrative Pharmacy . ISSN 1551-7411
76. Hashmi, F., Hassali, M., Khalid, A., Saleem, F., Aljadhey, H., Babar, Z. and Bashaar, M. (2017) ‘A qualitative study exploring perceptions and attitudes of community pharmacists about extended pharmacy services in Lahore, Pakistan’ BMC Health Services Research , 17, pp. 1-9. ISSN 1472-6963
77. Babar, Z., Kousar, R., Murtaza, G., Azhar, S., Khan, S. and Curley, L. (2017) ‘Randomized controlled trials covering pharmaceutical care and medicines management: A systematic literature review’ Research in Social and Administrative Pharmacy . ISSN 1551-7411
78. Ahmad, A., Patel, I., Khan, M. and Babar, Z. (2017) ‘Pharmaceutical waste and antimicrobial resistance’ The Lancet Infectious Diseases , 17 (6), pp. 578-579. ISSN 1473-3099 Zaheer-Ud-Din Babar, Ph.D. Page 22 of 50
79. Aziz, M., Fang, Y., Babar, Z. and Usman, M. (2017) ‘Hospital pharmacy services in Pakistan’ European Journal of Hospital Pharmacy . ISSN 2047-9956 80. Babar, Z.U.D., Siraj, A.M., Curley, C. (2017). A review of DTCA techniques: Apprising their success and impact on potential medication users. Research in Social and Administrative Pharmacy. 14, 3, p. 218-227 10 p.
81. Bashaar, M., Hassali, M.A., Saleem, F., Babar, Z.U.D (2017) Efficacy of international approaches to medicine price regulation and control: A scoping review (2017) Journal of Applied Pharmaceutical Science 7(04):227-241 82. Babar, Z.U.D., Gammie, T., Gnjidic. D., Reeve, E., Jordan, V., Hilmer, S.N., Hopper, I., Lu, CY (2017) Withdrawal of antihypertensive drugs in older people. Cochrane database of Systematic reviews. 2017 Issue 2 DOI 10.1002/14651858.CD012572http://onlinelibrary.wiley.com/doi/10.1002/14651 858.CD012572/epdf
83. Vogler, S., Vitry, A., Babar, Z.U.D.(2016) Oncology medicines in European countries, Australia and New Zealand: a cross-country price comparison study: The Lancet Oncology 17(1): 39-47http://dx.doi.org/10.1016/ S1470-2045(15)00449-0
84. Vogler, S., Zimmermann, N., Ferrario, A., Wirtz, VJ., Joncheere, KD., Pedersen, HB., Dedet, G., Paris, V., Mantel-Teeuwisse, AK., Babar, Z.U.D.(2016). Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Opportunities. Journal of Pharmaceutical Policy and Practice. 9:9DOI 10.1186/s40545-016-0056-8
85. Vogler, S., Zimmerman, N., Babar, Z.U.D(2016) Price comparison of high-cost originator medicines in European countries. Expert Review of Pharmacoeconomics and outcome research.http://dx.doi.org/10.1080/14737167.2016.1223543
86. Fisher, D., Wick, P., Babar, Z.U.D.(2016)Medicines and the future of health. BMC Medicine 14;169 http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0717-0
87. Atif, M.,Bashir, A., Saleem, Q., Hussain, R., Scahill, S., Babar, Z.U. (2016)Health- related quality of life and depression among medical sales representatives in Pakistan. Springer Plus. ; 5(1): 1048. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940353/ 88. Almarsdottir, AB .,Babar, ZUD. (2016) Future Methods in Pharmacy Practice Research. International Journal of Clinical Pharmacy, Published online 21st May 2016DOI 10.1007/s11096-016-0300-y 89. Gammie, T., Vogler, S., Babar, Z.U.D.(2016) Economic evaluation of hospital and community pharmacy services-A review of the literature (2010-2015) Annals of Pharmacotherapydoi:10.1177/1060028016667741 90. Shroff, Z., Bigdeli, M., Babar, ZUD., Wagner, A., Ghaffar, A.,Peters, DH. (2016) Using health markets to improve access to medicines: three case studies. Journal of Pharmaceutical Policy and Practice 9;19 DOI 10.1186/s40545-016-0067-5 Zaheer-Ud-Din Babar, Ph.D. Page 23 of 50 91. Gammie, T., Lu. C. Y., Babar, Z.U.D. (2015) Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS One 10(10): e0140002.doi:10.1371/journal.pone.0140002 92. Ragupathy R., Babar, Z.U. (2015). Uptake of new medicines: the Pharmaceutical Management Agency of New Zealand (PHARMAC) in the international context. New Zealand Medical Journal, 128:1416; 81-83. 93. Babar, Z. U. D., Lessing, C., Lessing, C., Stewart, J., & Sheridan, J. (2015). Evaluating general practitioners' opinions on issues concerning access to medicines in New Zealand. Journal of Pharmaceutical Health Services Research, 6:3;145-154. 10.1111/jphs.12100 94. Atif, M., Sulaiman, S. A., Shafie, A. A., &Babar, Z. U. (2015). Duration of treatment in pulmonary tuberculosis: are international guidelines on the management of tuberculosis missing something? Public health, 129:6;777-782. 10.1016/j.puhe.2015.04.010
95. Wahlster, P., Scahill, S.L, Lu, Y.C., Babar, Z . (2015). Barriers to access and use of High cost medicines: A review. Health Policy and Technology Available online 1 May 2015 http://www.sciencedirect.com/science/article/pii/S2211883715000465
96. Ragupathy, R., Babar, Z. -U. –D. (2015).Reply to Taylor and Wonder- Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand. Australian Health Review Availableonline 20 July 2015 http://dx.doi.org/10.1071/AH15070
97. Vogler,S. Kilpatrick, K., Babar, Z. -U. –D. (2015). Analysis of medicine prices between NZ and 16 European Countries, Value in Health: the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18:4, 484-492. http://dx.doi.org/10.1016/j.jval.2015.01.003
98. Nikfar, S., Babar, Z.-U.-D., Dinarvand, R., Kebriaeezadeh, A., Abdollahi, M. (2015). Consistent defined threshold and equity in health. DARU Journal of Pharmaceutical Sciences, 23 (1).
99. Bigdeli, M., Laing, R., Tomson, G., Babar, Z. -U. –D. (2015) Medicines and universal health coverage: challenges and opportunities Journal of Pharmaceutical Policy and Practice (2015) 8:8DOI 10.1186/s40545-015-0028-4
100. Jamshed, S.Q., Ibrahim, M.I.M., Hassali, M.A., Shafie, A.A., Babar, Z. -U. –D (2015) Understanding and Perception of Final Year Pharm D Students towards Generic Medicines in Karachi: A Quantitative Insight. Advances in Medical Education and Practice, 6; 359-366. http://dx.doi.org/10.2147/AMEP.S27762
101. Lu. C. Y., Lupton, C., Rakowsky, S., Babar, Z.U.,Degnan, D.R., Wagner, A.K. Patient Access Schemes in Asia-Pacific Markets: Current Experience and Future Potential. Journal of Pharm Prac& Policy(2015) 8:6 DOI 10.1186/s40545-014-0019- x
102. Babar, Z. -U. -D. Vitry, A. Differences in Australian and New Zealand medicines funding policies.Australian Prescriber 2014, Online First 8th Julyhttp://www.australianprescriber.com/online-first/54/differences-in- Zaheer-Ud-Din Babar, Ph.D. Page 24 of 50 australian-and-new-zealand-medicines-funding-policies
103. Ragupathy R, Babar ZUD, Mirza W, Daiya M, Chandra M, Yousif A, Girn M. New Zealand consumers’ perceptions of private insurance for pharmaceuticals. Springer Plus 2014, 3:587 http://www.springerplus.com/content/3/1/587
104. Atif M, Sulaiman SAS, Shafie AA, Ali I, Asif M, Babar ZU. Treatment outcome of new smear positive pulmonary tuberculosis patients in Penang, Malaysia. BMC Infectious Diseases 2014, 14:399, doi: 10.1186/1471-2334-14-399.
105. Atif M, Sulaiman SAS, Shafie AA, Ali I, Asif M, Babar ZU. Resource utilization pattern and cost of tuberculosis treatment from the provider and patient perspectives in the state of Penang, Malaysia. BMC Health Services Research 2014. 14:353, doi: 10.1186/1472-6963-14-353.
106. Babar ZU,Gray A, Kiani A, Vogler S, Ballantyne P, Scahill S. The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change. Journal of Pharmaceutical Policy and Practice 2014, 7:8 http://www.joppp.org/content/7/1/8 107. Babar, Z.U.D., Atif, M. Differential pricing of pharmaceuticals: A bibliometric review of the literature. Journal of Pharmaceutical Health Services Research (2014) 5; 3:149-156
108. Babar, Z. -U. -D., Susan, F. Identifying priority medicines policy issues for New Zealand. BMJ Open 2014; 4(5):e004415
109. Babar, Z. -U. -D., Scahill, S. L. Barriers to effective pharmacy practice in low and high-income countries. Integrated Pharmacy Research and Practice 2014:3 25– 27
110. Babar, Z. -U. -D., Kan, S.W., Scahill, S. L. Interventions promoting the use of generic medicines: A narrative review of the literature. Health Policy. 2014 Jun 14. doi: 10.1016/j.healthpol.2014.06.004.
111. Babar, Z. -U. -D., Polwin, A., Kan, S.W., McCarthy, S., Rasheed, F., Amerasinghe, A., Stewart, J.,Lessing, C., Ragupathy, R., Scahill, S. L. Exploring pharmacists' opinions regarding PHARMAC's interventions in promoting brand changes. Research in Social and Administrative Pharmacy 2014 April 13 doi: 10.1016/j.sapharm.2014.03.002
112. Atif, M., Sulaiman, S.A.S., SHAFIE, A.A., Asif, M., Sarfraz, M.K., Low, H.C., Babar, Z. U. Impact of tuberculosis treatment on health-related quality of life of pulmonary tuberculosis patients: a follow-up study. Health Qual Life Outcomes.2014 ;12(1):19. doi: 10.1186/1477-7525-12-19.
113. Atif, M., Toghrayee, Z., Low, H.C., Sulaiman, S.A.S., SHAFIE, A.A., Asif, M., Babar, Z. U., Sarfraz, M.K. Missing Data Analysis in Longitudinal Studies: Findings from a Quality of Life Study in Malaysian Tuberculosis Patients. Applied Research in Quality of Life. Feb 2014 doi: 10.1007/s11482-014-930. Zaheer-Ud-Din Babar, Ph.D. Page 25 of 50 114. WAHLSTER, P., SCAHILL, S.L, GARG, S., BABAR, Z. Identifying stakeholder opinion regarding access to "high-cost medicines: A systematic review of the literature. Central European Journal of Medicine (2014) 9; 3:513-527
115. Brown A, Atif M, Hesselberg E, Steele P, Wright C, Babar ZU. (2014) Human resources, health supply chains and access to essential medicines. Journal of Pharm Pract and Policy 7: I2;1-2
116. Cometto G, Babar ZU, Brown A, Hedman L, Campbell J. “Health supply chain personnel: an integral part of the health workforce. (2014) Journal of Pharm Pract and Policy 7; I1:2-3
117. Babar, Z. U., Lessing, C., Mace, C., & Bissell, K. (2013). The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle- income countries. Pharmacoeconomics, 31 (11), 1063-1082. doi:10.1007/s40273- 013-0095-9 118. Lockhart, M. M., Babar, Z. U., Carswell, C., & Garg, S. (2013). New Zealand's drug development industry. Int J Environ Res Public Health, 10 (9), 4339-4351. doi:10.3390/ijerph10094339 119. GARG, S., HASAN, R., SCAHILL, S.L., BABAR, Z (2013). A comparison of inspection practices of pharmaceutical manufacturing facilities in selected Arab countries and New Zealand. Eastern Mediterranean Health Journal Vol 11 No 10 120. Babar, Z. -U. -D., Scahill, S. L., Garg, S., & Akhlaq, M. (2013). A bibliometric review of pharmacy education literature in the context of low- to middle-income countries. Currents in Pharmacy Teaching and Learning, 5 (3), 218-232. doi:10.1016/j.cptl.2013.01.001
121. BABAR, Z., SCAHILL, VAUGHAN, C., KIANI, A. Southern Med Review to Journal of Pharmaceutical Policy and Practice: broadening the remit!Journal of Pharmaceutical Policy and Practice2013 6:1. 122. BABAR, Z., SCAHILL, S.L, PENGELLY, K., SHAW, J., GARG, S. Migrant health in New Zealand: Exploring issues concerning “medicines access and use”. Journal of Pharmaceutical Health Services Research (2013) 4: 41–49
123. SCAHILL, VAUGHAN, C., BABAR, Z. Ethnicity, Migration and Minority Groups: Medicines Access and Use in High-Income Economies. Southern Med Review (2012) 5; 2:1-2
124. HUSSAIN, A; MOHAMED IBRAHIM, M.I; BABER, Z.U. Using the potential of community pharmacies to promote rational drug use in Pakistan: An opportunity exists or lost? J Pak Med Assoc (2012) 62; 11:1217-1222.
125. JAMSHED, S.Q; IBRAHIM, M.I.M; HASSALI, M.A; MASOOD, I; LOW, B.Y; SHAFIE, A.A; BABAR, Z. Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: A questionnaire based study. South Med Rev. 2012 July; 5(1): 22–30.
Zaheer-Ud-Din Babar, Ph.D. Page 26 of 50 126. BABAR, Z., VAUGHAN, C., SCAHILL, S.L. Pharmacy practice: Is the gap between the North and South widening?South Med Rev. 2012 July; 5(1): 1–2 127. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471192/
128. BABAR, Z., GROVER. P., RACHAEL, P., BYE. L., SHERIDAN, J. A qualitative evaluation of general practitioners' perceptions regarding access to medicines in New Zealand. BMJ Open 2012;2:e000518, March 28, 2012
129. SCAHILL., S.L, BABAR., Z., WHEELER., A. Reducing the burden associated with bureaucratic practise in primary care: a welcome move by PHARMAC. Journal of Primary Healthcare. Vol 4, Number 1, March 2012
130. HASSALI., M.A.A; SHAFIE, A.A; BABAR., Z.U, KHAN, T. A study comparing the retail drug prices between Northern Malaysia and Australia. Journal of Pharmaceutical Health Services Research, 22 Feb 2012 DOI10.1111/j.1759- 8893.2011.00080.x
131. BABAR, Z, HASSALI, M.A.A, SHYONG, .TL, HIN, T.K, CIEN, C.S, BIN, L.S, ANANTHAM, S.C,KIRUBAKARAN, R, PING, S.B, CHUEN, C.S, SINGH,J.K.S. An Evaluation of Consumers’ Perceptions regarding “Modern Medicines” in Penang, Malaysia. J Young Pharm. 2012 Apr-Jun; 4(2): 108–113.
132. HUSSAIN, A; MOHAMED IBRAHIM, M.I; BABAR, Z.U. 'Compliance with legal requirements at community pharmacies: A cross sectional study from Pakistan', International Journal of Pharmacy Practice, 2011, 10.1111/j.2042- 7174.2011.00178.x.
133. SCAHILL, S.L; BABAR, Z. 'Social pharmacy: Borrowing tools and theories the world over', Southern Med Review, 4, (1), p1-1, 2011.
134. BABAR, Z; SCAHILL, S.L. 'The Authors’ Reply', Pharmacoeconomics, 29, (1), p83-86, 2011, 10.2165/11585510-000000000-00000. 135. JAMSHED, S.Q; IBRAHIM, M.I.M; SHAFIE, A.A; HASSALI, M.A; BABAR, Z. 'Generic medicines in Pakistan: A viable cost-effective option for consumers', European Journal of Clinical Pharmacology, 67, (9), p969-970, 2011. 136. BABAR, Z.U; SCAHILL, S.L. 'The authors' reply.', Pharmacoeconomics, 29, (5), p436-437, 2011, 10.2165/11585760-000000000-00000. 137. LOCKHART, M; BABAR, Z.U; GARG, S. 'Evaluation of policies to support drug development in New Zealand.', Health Policy, 96, (2), p108-117, 2010, 10.1016/j.healthpol.2010.01.012.
138. BABAR, Z; IBRAHIM, M.I.M; HASSALI, M.A.A. 'Pharmaceutical industry, innovation and challenges for public health: case studies from Malaysia and Pakistan', Journal of Pharmaceutical Health Services Research, 2011, 10.1111/j.1759- 8893.2011.00058.x.
139. LOCKHART, M.M; BABAR, Z.U; GARG, S. 'Drug Development in NZ: Can a Country Be a Cluster?'Drug Development Research, (72), p1-8, 2011, 10.1002/ddr.20489.
Zaheer-Ud-Din Babar, Ph.D. Page 27 of 50 140. LOCKHART, M.M; BABAR, Z.U.D; GARG, S. 'Clinical Trials in New Zealand: Progress, People, and Policies', DRUG DEVELOP RES, 72, (4), p299-304, 2011, 10.1002/ddr.20437.
141. LOCKHART, M.M; BABAR, Z; GARG, S. 'Drug development and research in New Zealand: Policies affecting the industry', Drug Development Research, 2011.
142. BABAR, Z; GROVER, P; STEWART, J; HOGG, M; SHORT, L; SEO, H.G; REW, A. 'Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in New Zealand', Research in Social and Administrative Pharmacy, 7, (3), p294-305, 2011.
143. BABAR, Z; JAMSHED, S; YEONG, S.W; IBRAHIM, M.I.M. 'Examination of students' interest in a public health pharmacy course in Malaysia', Currents in Pharmacy Teaching and Learning, 3, (3), p199-207, 2011.
144. JAMSHED, S.Q; HASSALI, M.A.A; IBRAHIM, M.I.M; BABAR, Z. 'Knowledge attitude and perception of dispensing doctors regarding generic medicines in Karachi, Pakistan: A qualitative study', Journal of the Pakistan Medical Association, 61, (1), p80-83, 2011.
145. BABAR, Z.U; STEWART, J; REDDY, S; ALZAHER, W; VAREED, P; YACOUB, N; DHROPTEE, B; REW, A. 'An evaluation of consumers' knowledge, perceptions and attitudes regarding generic medicines in Auckland.', Pharm World Sci, 32, (4), p440- 448, 2010, 10.1007/s11096-010-9402-0. (Impact factor 1.03)
146. JAMSHED, S.Q; HASSALI, M.A.A; IBRAHIM, M.I.M; SHAFIE, A.A; BABAR, Z. 'Knowledge, Perception and Attitude of Community Pharmacists towards Generic Medicines in Karachi, Pakistan: A Qualitative Insight', TROP J PHARM RES, 9, (4), p409-415, 2010. (Impact factor 0.820)
147. SCAHILL, S.L; BABAR, Z. 'Community pharmacy practice in high and low- income countries: Commonalities, differences and the tension of being "retailer" versus "primary health care provider"', Southern Med Review, 3, (2), p1-2, 2010.
148. BABAR, Z; SCAHILL, S.L. 'Evidence based pharmaceutical policy research: Is it all talk or does it contribute to improving health in developing countries?',Southern Med Review, 3, (1), p1-1, 2010.
149. HASAN, S.S; BAHARI, M.B; BABAR, Z.U; GANESAN, V. 'Antiepileptic drug utilisation and seizure outcome among pediatric patients in a Malaysian public hospital.’ Singapore Med J, 51, (1), p21-27, 2010. 150. BABAR, Z.U; SCAHILL, S.L. 'Is there a role for pharmacoeconomics in developing countries?',Pharmacoeconomics, 28, (12), p1069-1074, 2010, 10.2165/11584890-000000000-00000. 151. LOCKHART, M.M; BABAR, Z.U; GARG, S. 'New Zealand's drug development industry - Strengths and opportunities', New Zealand Medical Journal, 123, (1317), 2010.
Zaheer-Ud-Din Babar, Ph.D. Page 28 of 50 152. BABAR, Z; BESWICK, T. 'Southern med review: A new forum to publish "Local pharmaceutical policy in a global context"', Pharmacy World and Science, 31, (2), p143-144, 2009.
153. BABAR, Z; SCAHILL, S.L. 'Mapping the pharmaceutical situation in your country: First thing first.',Southern Med Review, 2, (1), p1-1, 2009.
154. AHMED M, H.A; IBRAHIM M, I.M; BABAR, Z. 'Affordability of essential medicines used for treating chronic diseases in Malaysia: An academic perspective.’ The Internet Journal of Third World Medicines, 8, (1), 2009, http://www.ispub.com/journal/the_internet_journal_of_third_world_medicine/curr ent.html.
155. BABAR, Z.D; IZHAM, M.I.M. 'Effect of privatization of the drug distribution system on drug prices in Malaysia', Public Health, 123, (8), p523-533, 2009. 156. JAMSHED, S.Q; BABAR, Z.U.D; IBRAHIM, M.I.M; HASSALI, M.A.A. 'Generic medicines as a way to improve access and affordability: A proposed framework for Pakistan', Journal of Clinical and Diagnostic Research, 3, (3), p1596-1600, 2009.
157. JAMSHED, S; BABAR, Z; IZHAM, M; IBRAHIM, M. 'PharmD in Pakistan, American Journal of Pharmaceutical Education, 73, (1), 2009. 158. SCAHILL, S; HARRISON, J; CARSWELL, P; BABAR, Z.U. 'Organisational culture: an important concept for pharmacy practice research.’ Pharm World Sci, 31, (5), p517-521, 2009, 10.1007/s11096-009-9318-8.
159. BABAR, Z. 'Disseminating 'medicine access and use' research', Southern Med Review, 1, (1), p2-2, 2008.
160. DIN BABAR, Z; AWAISU, A. 'Evaluating community pharmacists' perceptions and practices on generic medicines: A pilot study from Peninsular Malaysia', Journal of Generic Medicines, 5, (4), p315-330, 2008. 161. BABAR, Z.U; JAMSHED, S. 'Social pharmacy strengthening clinical pharmacy: why pharmaceutical policy research is needed in Pakistan?', Pharm World Sci, 30, (5), p617-619, 2008, 10.1007/s11096-008-9246-z (Impact factor 1.03)
162. BABAR, Z.U; BUKHARI, N.I; SARWAR, W; EFENDIE, B; PEREIRA, R; MOHAMED, M.H. 'A preliminary study on the effect of pharmacist counseling on awareness of and willingness to quit smoking in Malaysian population.', Pharm World Sci, 29, (3), p101-103, 2007, 10.1007/s11096-005-2905-4. 163. JAMSHED, S; BABAR, Z.U; MASOOD, I. 'The PharmD degree in developing countries.',American journal of pharmaceutical education, 71, (6), p125-125, 2007. (Impact factor 1.025)
164. BABAR, Z.U. 'Pakistan's National University of Pharmaceutical Sciences.', American journal of pharmaceutical education, 70, (5), p123-123, 2006. 165. BABAR, Z; ZAINI, N.R.M. 'Self-medication in Malaysia: A case of midazolam poisoning in a tertiary care hospital', International Journal of Pharmacy Practice, 14, (2), p159-159, 2006.
Zaheer-Ud-Din Babar, Ph.D. Page 29 of 50 166. BABAR, Z.U; IBRAHIM, M.I; SINGH, H; BUKAHRI, N.I; CREESE, A. 'Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.’ PLoS Med, 4, (3), pe82, 2007, 10.1371/journal.pmed.0040082.
167. BABAR, Z.U. Medicine prices in Malaysia: Myth or reality. Journal of Advancement of Science and Arts (2006) 1; 1:2-8
168. BABAR, Z; NUR, R.M.Z; CHOON, W.Y. 'Harm reduction program and methadone poisoning: Implications for pediatric public health in Malaysia', Journal of Pharmacy Practice, 19, (5), p280-281, 2006.
169. BABAR, Z.U, IBRAHIM M, IZHAM. M, Challenges and opportunities in conducting a medicine pricing survey in Malaysia. Essential Drug Monitor, No 34 Geneva: World Health Organization (2005) 34:31 170. BABAR, Z. 'Pharmacy education and practice in Pakistan', AM J PHARM EDUC, 69, (5), 2005.
171. BABAR, Z.U.D; IBRAHIM, M.I.M; BUKHARI, N.I. 'A pricing analysis of cardiovascular and blood products after privatization of drug distribution system in Malaysia', Journal of Pharmaceutical Finance, Economics and Policy, 14, (3), p3-25, 2005.
172. BABAR, Z.U; IBRAHIM MOHAMED, I.M; BUKHARI, N.I. 'Medicine utilisation and pricing in Malaysia: The findings of a household survey', Journal of Generic Medicines, 3, (1), p47-61, 2005.
173. BABAR, Z.U.D; IBRAHIM, M.I.M; BUKHARI, N.I. 'Effect of privatization of the General Medical Store on the prices of anti-infectives in Malaysia', Journal of Pharmaceutical Finance, Economics and Policy, 13, (3), p3-26, 2004.
174. BABAR, Z.U., IBRAHIM M, IZHAM. M. Consumer perception and attitudes towards affordability of medicines in Malaysia. Essential Drug Monitor, 33, Geneva: World Health Organization (2003) 33:18-19
Research Reports [Peer Reviewed]
• BABAR, Z.U., IBRAHIM M, IZHAM. M., SINGH, H., BUKHARI, N.A Survey of Medicine Prices in Malaysia by using WHO/HAI methodology, October 2005. Malaysia. Available at: http://www.haiweb.org/medicineprices/surveys/200410MY/survey_report.pdf. Printed copy published by UCSI Centre for Research Excellence & Universiti Sains Malaysia, Malaysia. ISBN: 978-983-43337-0-6
• Babar ZU, Lessing R, Bissell K, Mace C. Essential medicines prices, availability and affordability. Chapter in the Global Asthma Report 2011. Published by International Union Against Tuberculosis and Lung Disease and The International Study of Asthma and Allergies in Childhood Diseases. Paris, France. ISBN: 978-2-914365-83- 3 Zaheer-Ud-Din Babar, Ph.D. Page 30 of 50
Encyclopaedia
Encyclopedia of Clinical Pharmacy and Practice (Editor-in-Chief)
Babar ZUD. Encyclopaedia of Pharmacy Practice and Clinical Pharmacy. 24th June 2019; Elsevier., ISBN: 9780128127353https://www.elsevier.com/books/encyclopedia-of- pharmacy-practice-and-clinical-pharmacy/babar/978-0-12-812735-3
The encyclopaedia has 180 chapters and is divided into 5 sections (a) Pharmacy practice (b) Pharmacy practice research methods (c)Clinical pharmacy and pharmacotherapy) (d) Clinical Pharmacy education, professional standard and workforce (e) Pharmacoepidemiology and pharmacovigilance (f) Socio-behavioral and administrative pharmacy. It will also cover pharmacy practice research, pharmacovigilance, pharmacoeconomics, social and administrative pharmacy, public health pharmacy, pharmaceutical systems
There is widespread coverage in the press: https://www.elsevier.com/connect/how-addressing-knowledge-gaps-in-pharmacy-and- medicine-can-impact-global- health?sf211857924=1&fbclid=IwAR05n6iM7d0s_AKEpp5ciykPI2WyYmSvvo5jiPanTTelZ6 K0WbQ_CnaYbGo https://pharmacyinpractice.scot/2019/02/20/podcast-professor-zaheer-ud-din-babar- how-to-write-a-pharmacy- encyclopaedia/?fbclid=IwAR2PEcMYysvJyXIb6F7PHnNNjcIbPQuuDpI6H7MmNjHsGhIynjan 5vfMyYE
Books
1. The reality of medicine prices in Malaysia
BABAR, Z.U., IBRAHIM M, IZHAM. M., SINGH, H., BUKHARI, N.I. The reality of medicine prices in Malaysia. Penerbit Universiti Sains Malaysia 2010, Penang, Malaysia. ISBN 978-983-861-427-6
2. Pharmaceutical Prices in the 21st Century
BABAR, Z.U., (Ed). Pharmaceutical Prices in the 21st Century 2015, X, 411 p. http://www.springer.com/adis/book/978-3-319-12168-0 The book covers a range of pharmaceutical pricing issues. It has twenty-two chapters in total; the nineteen chapters are country case studies ranging from an array of high, middle and low-income countries. The country case study include Australia, Canada, China, Egypt, Ethiopia, Finland, India, Italy, Malaysia, New Zealand, Norway, Qatar, South Korea, South Africa, Sweden, Turkey, United Arab Emirates, United States of America and Vietnam. Zaheer-Ud-Din Babar, Ph.D. Page 31 of 50
3. Pharmacy Practice Research Methods, 1st Edition
BABAR, Z.U., (Ed). Pharmacy Practice Research Methods (ISBN: 978-3-319-14671- 3)2015, X, 235 p. http://www.springer.com/adis/book/978-3-319-14671-3
This book presents a contemporary view of pharmacy practice research covering theories, methodologies, models and techniques that are applicable. It has thirteen chapters covering the range of quantitative, qualitative, action research and mixed methods as well as management theories underpinning change in pharmacy practice. “Pharmacy Practice Research Methods” examines the evidence and impact as well as explores the future.
4. Economic evaluation of pharmacy services
BABAR, Z.U. Economic evaluation of pharmacy services (Print ISBN: 9780128036594) Elsevier, Nov 2016 http://store.elsevier.com/product.jsp?isbn=9780128037003&pagename=search
This book delivers a practical guide for conducting economic evaluations of hospital and community pharmacy services. It also documents the literature around health economic evaluation and innovative pharmacy services. The book also guides the development of a standardized health economic evaluation tool to evaluate these services.
5. Pharmaceutical policy in countries with developing health systems
BABAR, Z.U. Pharmaceutical policy in countries with developing health systems (Print ISBN: 978-3-319-51672-1) Adis/Springer, April, 2017 http://www.springer.com/gp/book/9783319516721#aboutBook
6. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries: Present Challenges and Future Solutions
Mohamed Ibrahim, M., Wertheimer, A. and Babar, Z. (2017) Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries: Present Challenges and Future Solutions . United Kingdom: Elsevier. ISBN 978-0128112281
7. Equitable access to high cost pharmaceuticals
Babar, ZUD .Equitable access to high cost pharmaceuticals. ISBN9780128119457 Elsevier/Academic Press Feb 2018https://www.elsevier.com/books/equitable- access-to-high-cost-pharmaceuticals/babar/978-0-12-811945-7
8. Global Pharmaceutical Policy
Zaheer-Ud-Din Babar, Ph.D. Page 32 of 50 BABAR, Z.U. Global Pharmaceutical Policy. PalgraveMacmillan, 2020 Hardcover ISBN 978-981-15-2723-4 , June 2020 https://www.palgrave.com/gp/book/9789811527234
9. Pharmacy Practice Research Methods 2nd Edition
BABAR, Z.U. Pharmacy Practice Research Methods 2nd Edition Springer, April 2020 https://link.springer.com/book/10.1007/978-981-15-2993-1
10. Pharmacy Practice Research Case Studies 1s Edition
BABAR, Z.U. Pharmacy Practice Research Case Studies 1st Edition Elsevier, Jan 2021 (In Press)
Book Chapters
1. Babar, Z.U., Jamshed, S., Malik, A., Gilani, A.H. (August 2013). ' The Pharmaceutical Industry, Intellectual Property Rights and Access to Medicines in Pakistan. The New Political Economy of Pharmaceuticals pp.167–184. [Online] Available at: http://www.palgraveconnect.com/pc/doifinder/10.1057/9781137315854.0014 2. Ragupathy R, Kilpatrick K, Babar ZUD (2015) Pharmaceutical pricing in New Zealand. Z.-U.-D. Babar (ed.), Pharmaceutical Prices in the 21st Century, DOI 10.1007/978-3-319-12169-7_11
3. Zaidi STR, Babar ZUD. Applying pharmacoeconomic methods in community and hospital pharmacy research. Z.-U.-D. Babar (ed.) Pharmacy Practice Research Methods 2015, X, 235 p. 12 illus., 3 illus. in color.http://www.springer.com/adis/book/978-3-319-14671-3
4. Babar ZUD, Almarsdottir AB, Future of Pharmacy Practice Research (ed.) Z.-U.-D. Babar (ed.) Pharmacy Practice Research Methods 2015, X, 235 p. 12 illus., 3 illus. in color.http://www.springer.com/adis/book/978-3-319-14671-3
5. Ahmed A, Kheir N, Al-Salimy N, Babar ZUD, , Pharmacist’ attitudes towards pharmacy practice research Z.-U.-D. Babar (ed.) Pharmacy Practice Research Methods 2015, X, 235 p. 12 illus., 3 illus. in color.http://www.springer.com/adis/book/978-3-319-14671-3
6. T. Gammie , S. Vogler, Z.-U.-D. Babar. Economic Evaluation of Community and Hospital Pharmacy Services: An Introductory Review. Babar, Z.U (ed.) Economic evaluation of pharmacy services 2016, x, 248 p ISBN: 9780128036594
7. Z.-U.-D. Babar, R.Edlin. Economic Evaluation of a Medicines Management Model in New Zealand. Babar, Z.U (ed.) Economic evaluation of pharmacy services 2016, x, 248 p ISBN: 9780128036594 Zaheer-Ud-Din Babar, Ph.D. Page 33 of 50 8. M. Atif, M. Ahmad, Q. Saleem, L. Curley, Z.-U.-D. Babar. Pharmaceutical Policy in Pakistan. Z.-U.-D. Babar (ed.), Pharmaceutical Policy in Countries with Developing Healthcare Systems, 2017,x, 424 ISBN: 978-3-319-51672-1 DOI 10.1007/978-3- 319-51673-8_3 http://www.springer.com/gb/book/9783319516721
9. S. Dhingra, S.Maharaj, Z.-U.-D. Babar. Pharmaceutical Policy in Trinidad and Tobago. Z.-U.-D. Babar (ed.), Pharmaceutical Policy in Countries with Developing Healthcare Systems, 2017,x, 424 ISBN: 978-3-319-51672-1 DOI 10.1007/978-3-319-51673- 8_3 http://www.springer.com/gb/book/9783319516721
10. H. Håkonsen, I. Emmerick, Z.-U.-D. Babar. Introduction to pharmaceutical policy. Z.- U.-D. Babar (ed.), Pharmaceutical Policy in Countries with Developing Healthcare Systems, 2017,x, 424 ISBN: 978-3-319-51672-1 DOI 10.1007/978-3-319-51673- 8_3 Preshttp://www.springer.com/gb/book/9783319516721
11. W.Kaplan, N. Boskovic, D. Flanagan, S. Lalany, C.Y. Lin, Z.-U.-D. Babar. Pharmaceutical Policy in Countries with Developing Healthcare Systems: Synthesis of Country Case Studies. Z.-U.-D. Babar (ed.), Pharmaceutical Policy in Countries with Developing Healthcare Systems, 2017,x, 424 ISBN: 978-3-319-51672-1 DOI 10.1007/978-3- 319-51673-8_3
12. Babar, Z. -U., & Scahill, S. L. (2018). Pharmaceutical Policy: Synthesis, Themes, and Future Directions. In M. Izham Mohamed Ibrahim, A. I. Wertheimer, & Z. -U. Din Babar (Eds.), Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries: Present Challenges and Future Solutions. Elsevier: Academic Press, 419– 437. ISBN: 9780128112281 13. Hasan, S. S., Lu, C. Y., Babar, Z. U (2018). Access to high-cost medicines: An overview. Z. -U. Din Babar (Ed.), Equitable Access to High-Cost Pharmaceuticals. Elsevier: Academic Press, 1-10. ISBN: 978-0-12-811945-7 14. Rehman, K., Bukhari, N. I., Babar, Z. U (2018). Equitable access to Biosimilars: An overview. Z. -U. Din Babar (Ed.), Equitable Access to High-Cost Pharmaceuticals. Elsevier: Academic Press, 129-142. ISBN: 978-0-12-811945-7 15. Curley, L. E., Jensen, M., Babar, Z. U., Ram, S (2018). Equitable Access to high-cost medicines in New Zealand. Z. -U. Din Babar (Ed.), Equitable Access to High-Cost Pharmaceuticals. Elsevier: Academic Press, 183-197. ISBN: 978-0-12-811945-7 16. Babar, Z. U.-D., Hussain, R. & Hasan, S. S. 2018. Medicine Prices in Asia-Pacific Countries. In: Vogler, S. (ed.) Medicine Price Surveys, Analyses and Comparisons Evidence and Methodology Guidance, Vogler S (2018). ISBN: 9780128132128
17. Bain, A., Kavanagh, S., Babar, Z.-U.-D., (2019) Prescribing insulin for people with diabetes in secondary care: recommendations and future direction, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353 18. Hasan, S. S., Know, C. S., Babar, Z.-U.-D., (2019) Access to high cost medicines, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353 19. Taychakhoonavudh, S., Babar, Z.-U.-D., (2019) Pharmaceutical company sponsored medication assistance program, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353 Zaheer-Ud-Din Babar, Ph.D. Page 34 of 50 20. Baines, D., Babar, Z.-U.-D., (2019), Technology and pharmacy: Theory, practice and the future vision, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
21. Atif, M., Malik, I., Dawoud, D., Gilani, A. H., Ahmed, N., Babar, Z.-U.-D., (2019), World Health Organization essential medicines list and its impact on improving the use of medicines, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
22. Babar, Z.-U.-D., Hasan, S. S., Suleman, F., (2019), Strengthening health systems in low and middle-income countries through evaluating cancer medicine prices, availability and affordability: A case study and proposal, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
23. Hussain, R., Hadeed, T., Hassali, M. A., Patel, M., Babar, Z.-U.-D., (2019), Role of pharmacist in provision of clinical services in prisons, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353 24. Hussain, R., Hassali, M. A., Babar, Z.-U.-D., (2019), Quantitative methods in pharmacy practice research, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
25. Hussain, R., Hassali, M. A., Patel, M., Babar, Z.-U.-D., (2019), Publication bias, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
26. Ramzan, S., Babar, Z.-U.-D., (2019), Mixed methods research in pharmacy practice, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
27. Bain, A. L., Kavanagh, S., Babar, Z.-U.-D., (2019), Prescribing insulin for people with diabetes in secondary care: Messages and future direction, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353 28. Afzal, S. K., Hasan, S. S., Babar, Z.-U.-D., (2019), Direct oral anti-coagulants and the patient reported outcomes: Synthesis and advances, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
29. Saleem, Z., Tauqeer, F., Babar, Z.-U.-D., (2019), Meta synthesis of qualitative research in pharmacy practice research, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
30. Rasheed, H., Ibrahim, M. I. M., Babar, Z.-U.-D., (2019), Evidence-Based Pharmacy Practice in Lower- and Middle-Income Countries: Issues, Challenges and Synthesis: Gaps in evidence for LMIC, Encyclopaedia of Pharmacy Practice and Clinical Pharmacy, Babar, Z-U-D (2019). ISBN:9780128127353
31. Hussain, R., Hassali, M. A., Babar, Z.-U.-D., (2020) Medicines safety in a gloablised context. Global Pharmaceutical Policy, Babar, Z-U-D (Ed). PalgraveMacmillan https://www.palgrave.com/gp/book/9789811527234 Zaheer-Ud-Din Babar, Ph.D. Page 35 of 50 32. Malik, I., Atif, M., Scahill, S., Babar, Z.-U.-D., (2020) Pharmacy practice and policy research in Pakistan: A review of literature between 2014-2019. Global Pharmaceutical Policy, Babar, Z-U-D (ed). PalgraveMacmillan ISBN 978-981-15- 2723-4 https://www.palgrave.com/gp/book/9789811527234
33. Razzakova , C.M., Ziganshina , L.E., Hasan, S.S., Babar, Z.-U.-D., (2020) Access to medicines: Case studies from Russia and Kyrgyzstan. Global Pharmaceutical Policy, Babar, Z-U-D (ed). PalgraveMacmillan ISBN 978-981-15-2723-4 https://www.palgrave.com/gp/book/9789811527234
34. Grintsova, O., Babar, Z.-U.-D., (2020) Access and use of medicines in Ukraine. Global Pharmaceutical Policy, Babar, Z-U-D (ed). PalgraveMacmillan ISBN 978-981-15- 2723-4 https://www.palgrave.com/gp/book/9789811527234
35. Babar, Z.-U.-D., Scahill, S. (2020) Medicines access, use and pharmaceutical health system issues: Reflections, thoughts and points to consider. Global Pharmaceutical Policy, Babar, Z-U-D (ed). PalgraveMacmillan ISBN 978-981-15-2723-4 https://www.palgrave.com/gp/book/9789811527234
36. Haloud, R., Babar, Z.-U.-D. (2020) Grounded theory in pharmacy practice research. Pharmacy Practice Research Methods 2nd Edition, Babar, Z-U-D (2020). Springer https://link.springer.com/chapter/10.1007/978-981-15-2993-1_8
37. Babar, Z.-U.-D. Almarsdottir, A.B (2020) Future and pharmacy practice research. Pharmacy Practice Research Methods 2nd Edition, Babar, Z-U-D (2020). Springer https://link.springer.com/chapter/10.1007/978-981-15-2993-1_13
38. Hasan, S.S., Kairuz, T., Thiruchelvam, K., Babar, Z.-U.-D. (2020) Systematic reviews and meta-analysis in pharmacy practice. Pharmacy Practice Research Methods 2nd Edition, Babar, Z-U-D (2020). Springer https://link.springer.com/chapter/10.1007/978-981-15-2993-1_12
Cochrane Review
Lead Investigator in the Cochrane Review, Withdrawal of antihypertensive drugs in the older people (Hypertension Group). The other investigators are from Harvard Medical School, Monash University and University of Sydney, Australia.
This Cochrane Review is funded by the by the Cochrane Review Support Programme (CRSP) through a competitive process. Here is the link to the funding announcement. http://www.cochrane.org/news/cochrane-announces-funding-support-10-new-cochrane- reviews
Report – Commissioned • Babar ZUD. Evaluation of the RPS community pharmacy research ready accreditation programme in the United Kingdom. Feb 2019 Zaheer-Ud-Din Babar, Ph.D. Page 36 of 50
• Veronika J. Wirtz, Sabine Vogler, Lena Lepuschütz, Babar, Z.U.D., Warren A. Kaplan, Erika L. Crable. International Assessment of Remuneration Models for Community and Hospital Pharmacy. Technical Report Submitted to International Pharmaceutical Federation (FIP), 31st Jan 2015.
• ASHTON, T., Babar, Z.U. Funding high cost targeted Medicines: Improving the New Zealand approach. An independent review of a report by Castalia Strategic Advisors', (Submitted to PHARMAC), August 2008
Grants Reviewer
Funding bodies of Australia, UK, Croatia Medical Research Council (MRC), UK
Consultancy assignments/Advisory Role/Investigator in projects
Consultant (2020)
Pharmaceutical Group of the European Union (PGEU2020): A vision for community pharmacy in Europe 2030.
Advisor (2019/2020)
Advisor on Pakistan’s National Medicines Policy 2020-2023, working with the Pakistan’s Minister of Health on the inception, development and editing of the draft National Medicines Policy. Appointed in the role in August 2019.
Independent Expert (2019/2020) “Systematic reviews for updating an evidence-informed guideline on country pharmaceutical pricing policies”. A project Commissioned by the WHO/undertaken by the Utrecht University, the Netherlands.
Advisor (2019/2020) Pharmaceutical System Strengthening Technical Advisory Group, USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Programme, Management Sciences for Health, Arlington, USA
Co-Investigator (Sept 2019- March 2020)
Pharmacy Council of Pakistan (PCP) Need Assessment. Conceptualization, Review the international/national literature on Pharmacy Training and registration, interviews and the final report. Working with the PI and JSI Institute, A USAID funded project.
Consultant (Abbott Switzerland, Dec 2019-till date)
Zaheer-Ud-Din Babar, Ph.D. Page 37 of 50 “Public private partnerships and it’s impact on Universal Health Coverage”
Consultant -World Bank (April 2016-April 2017)
I have worked with the World Bank as a lead consultant to strengthen pharmaceutical system in Bangladesh. The project involves pharmaceutical system evaluation and acting as an advisor to a medicines pricing study in Bangladesh.
Consultant -International Pharmaceutical Federation (2013)
• In June 2013, I acted as a co-investigator on a project funded by International Pharmaceutical Federation. The project entitled “International remuneration models of hospital and community pharmacies” and is led by Veronika Wirtz of Boston School of Public Health. Consultant- International Union Against Tuberculosis and Lung Disease (2011)
• In April 2011, I was appointed as a consultant/Principal Investigator by International Union Against Tuberculosis and Lung Disease (The Union) to measure the prices of essential asthma medicines in 50 low and middle-income countries. The study has now been completed and is being published as a Chapter in the Global Asthma Report. The report will be presented in a UN summit in New York on 19-20th Sep 2011. We are also in the process of writing a paper to be published in a major scientific journal.
Consultant-World Health Organization/Health Action International (2010)
• In July 2010, I was appointed as a consultant by Health Action International (HAI) to undertake a project on vaccine pricing. The vaccine work involved research and analysis on vaccine procurement, pricing, supply chain, research and development and international financing mechanisms. The work was completed in Sep 2010 and will contribute to a global WHO report.
• In August 2010, I was appointed as a consultant by Health Action International (HAI) to undertake a project in the area of differential pricing. The consultancy also includes an assessment of the impact of differential pricing initiatives on improving medicine affordability and availability specifically in the areas of HIV/AIDS, TB, malaria, cancer and reproductive health. The work will be published as a briefing paper on “differential prices” by Health Action International. The work was completed in Dec 2010.
Abstracts/Papers in Journal Supplements (Referred)
1. Nagaria, R., Hasan, S.S., Babar, Z.U.D. (2020) Pharmaceuticals and public policy in the future of pharmacy: a review of literature. Journal of Pharmaceutical Policy and Practice 13(Suppl 1):3 https://doi.org/10.1186/s40545-019-0201-2 2. Vogler, S., Zimmermann, N., Haasis, M, A., Babar, Z.U.D., Busse, R., Balbino, J.E., Teeuwisse, A.M., Suleman, F., Wirtz, V.J (2019) Can pharmaceutical pricing and reimbursement policies make a difference in promoting equitable access to Zaheer-Ud-Din Babar, Ph.D. Page 38 of 50 affordable medicines? From diagnosis to sustainable impact . Journal of Pharmaceutical Policy and Practice 2019 12(Suppl 1):34 3. Vogler, S., Zimmermann, N., Ferrario, A., Wirtz, V.J., Babar, Z.U.D. (2015). Challenges and opportunities for pharmaceutical pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice. doi:10.1186/2052-3211-8-S1-E1 4. Vogler, S., Zimmermann, N., Wirtz, V.J., Babar, Z.U.D. (2015). Policies beyond the crisis: lesson learned. Journal of Pharmaceutical Policy and Practice.doi:10.1186/2052-3211-8-S1-E2 5. Vogler, S., Zimmermann, N., Wirtz, V.J., Babar, Z.U.D.Policy cooperation and interface issues. Journal of Pharmaceutical Policy and Practice 2015, 8(Suppl 1): E3 (5 October 2015)doi:10.1186/2052-3211-8-S1-E3 6. Babar,Z.U.D., Ali, A., Kim, C., Mcintosh, J., Namdas, M., Rodrigues, E., Vallabh, K., Rew, A. (2015). Access to subsidised medicines, cost of medicines and health outcomes: exploring general practitioners' perceptions and experiences. Journal of Pharmaceutical Policy and Practice, 8(Suppl 1): O6 (5 October 2015) 7. Atif M, Sulaiman SAS, Shafie AA, Ali I, Asif M, Babar ZU. Impact of Tuberculosis Treatment on Health- Related Quality of Life of Pulmonary Tuberculosis. Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
8. JAMSHED, S., IBRAHIM, M. I. M., HASSALI, M. A. A., SHAFIE, A.A., BABAR, Z. U. (2012).Do Community Pharmacists Understand the Concept of Generic Medicines? A Quantitative Insight from Karachi, Pakistan. Research in Social and Administrative Pharmacy Vol. 8, Issue 6, Pages e16-e17
9. JAMSHED, S., IBRAHIM, M. I. M., HASSALI, M. A. A., SHAFIE,A.A.,BABAR, Z. U. (2012). Do Hospital Pharmacists in Pakistan Understand the Concept of Generic Medicines? A Mixed-Method Approach. Research in Social and Administrative Pharmacy Vol. 8, Issue 6, Page-e17
10. JAMSHED, S., IBRAHIM, M. I. M., HASSALI, M. A. A., SHAFIE, A.A., BABAR, Z. U. (2012). Do Consumers in Pakistan Understand the Concept of Generic Medicines? A Quantitative insight. Research in Social and Administrative Pharmacy Vol. 8, Issue 6, Page e16
11. JAMSHED, S., HASSALI, M. A. A., IBRAHIM, M. I. M., BABAR, Z. U. Knowledge, attitude and perception of consumers towards generic medicines in Karachi, Pakistan. Malaysian Journal of Pharmacy, 1, S43, 2009
12. BABAR, Z.U., IBRAHIM M, IZHAM. M., BUKHARI, N.I., KRISHNAN, S. Effect of Privatization of Malaysian Drug Distribution System on the Prices of Drugs Affecting Central Nervous System. The Journal of Mental Health Policy and Economics, Vol. 8, Supplement 1, 2005.
13. BABAR, Z.U., IBRAHIM M, IZHAM. M., BVS, LOKESH. Affordability & Differential Drug Prices in Malaysia. Malaysian Journal of Pharmacy Vol 1 No4 December 2004.
14. BABAR, Z.U., BUKHARI, N.I., SARWAR, W. Genetically modified food: Does pharmacist have a role to play? Malaysian Journal of Pharmacy Vol 1 No 4 December 2004.
Zaheer-Ud-Din Babar, Ph.D. Page 39 of 50 15. BABAR, Z.U., BUKHARI, N.I. Smoking and drinking patterns in adults. Malaysian Journal of Pharmacy Vol 1 No4 December 2004.
16. YEONG, S.W., EFFENDIE, B., BUKHARI, N.I., BABAR, Z.U. Public perception of the pharmacy profession. Malaysian Journal of Pharmacy Vol 1 Issue 4 December 2004.
17. BABAR, Z.U., HASSAN, Y., AZIZ, N.A., EASAW, S. Erythematous maculo-papular rash induced by Fansidar. Asia Pacific Journal of Pharmacology 2000; June (14) Supplement 2.
Conference Presentations (Referred)
1. Rida NA, Ibrahim MIM, Owusu Y, Babar ZUD. Are cardiovascular medicines in Qatar and Lebanon affordable? An analysis and comparison of two developing middle- eastern countries. ISPOR Europe 2018. Barcelona, Spain. November 10-14, 2018. 2. Vogler S, Kilpatrick K, Babar ZU. Analysis of medicine prices in New Zealand and 16 European countries. EuroDURG 2014 Groningen, The Netherlands, August 27-29 2014
3. Babar ZU, Lessing C, Sheridan J . Evaluating general practitioners’ opinions on issues concerning access to medicines and generic medicines in New Zealand. WHO Collaborating Centre for Pharmaceutical Policy and Regulation,7-8th January 2014, Utrecht, The Netherlands 4. CHANDRA, M., DAIYA, M.M., MANINDER, S.G., WASIF, R.M., YOUSIF, A., RAGUPATHY, R. BABAR, Z.U. Private Insurance for Pharmaceuticals. Evaluating Consumers’ Perspectives in Auckland. Asia Pacific Conference on National Medicines Policies, 26th-29th May 2012, Sydney, Australia.
5. Babar ZU, Shaw J, Brailsford I. An evaluation of students’ knowledge, perceptions, understanding and learning of “pharmacoeconomics” in an undergraduate pharmacy programme. International Life Long Learning Conference 29th June -1st July 2011, Rotorua, New Zealand. 6. LOCKHART, M., BABAR, Z U., GARG, S. “The state of clinical research in New Zealand” NZACRes Conference 27 August 2010, Auckland 7. BABAR,ZU., STEWART, J., REDDY, S., ALZAHER,W., VAREED, P., YACOUB,N., DHROPTEE, B., REW, A. Quality use of generic medicines in the Auckland region: An evaluation of consumers’ knowledge, perception and attitude. NZHPA Conference 3- 5th Sep 2010, Hamilton, New Zealand
8. LOCKHART, M., BABAR, ZU., GARG, S. “Policy options to support drug development in New Zealand”. 6th Health Services and Policy Research Conference, Brisbane, 25- 27 November 2009
9. JAMSHED, S., HASSALI, M. A. A., IBRAHIM, M. I. M., BABAR, Z. U. Understanding and perception of final year pharmacy student towards generic medicines in Pakistan: An exploratory qualitative study. 16th International Social Pharmacy Workshop, 23- 26 August 2010, University of Lisbon, Portugal Zaheer-Ud-Din Babar, Ph.D. Page 40 of 50
10. JAMSHED, S., HASSALI, M. A. A., IBRAHIM, M. I. M., Shafie, A.A, BABAR, ZU. Do low income groups in Pakistan understand the concept of generic medicines? ISPOR 4th Asia-Pacific Conference, 5-7 September 2010, Phuket Thailand
11. JAMSHED, S., HASSALI, M. A. A., IBRAHIM, M. I. M., Shafie, A.A, BABAR, ZU. Do high income groups in Pakistan Understand the concept of generic medicines? ISPOR 13th Annual European Congress 6-9 November 2010 Prague, Czech Republic.
12. JAMSHED,S., HASSALI, M. A. A., IBRAHIM, M. I. M., BABAR, Z. U. Understanding and perceptions of generic medicines among hospital pharmacists in Pakistan. 69th International Congress of FIP 3 - 8 September 2009, Istanbul, Turkey
13. LOCKHART, M., BABAR, ZU., GARG, S. Methodology to evaluate the drug development industry in New Zealand,NZBio Conference, 9-11 March 2009, Auckland, New Zealand
14. HASAN, SS., BAHARI, M.B., BABAR, Z.U., GANESAN, V. Anti-epileptic drug utilization and seizure outcome among paediatric patients in a Malaysian Public Hospital. The 8th Asian Conference on Clinical Pharmacy.1-4th July 2008, Surabaya Indonesia
15. JAMSHED, S., BABAR, ZU., HASSALI, M. A. A., IBRAHIM, M. I. M., MASOOD, M.I., HUSSAIN, A., AZHAR, S.Evaluating perception, knowledge and attitude of dispensing doctors towards generic medicines in Pakistan. 22nd Federation of Asian Pharmaceutical Association Congress, 7th-10 November 2008, Singapore.
16. BABAR, Z.U. Scientific inquiry & pharmaceutical policy: A preliminary analysis from New Zealand. National Medicines Symposium, 14-16th May 2008, Canberra, Australia
17. BABAR, Z.U., AWAISU A. Evaluating community pharmacists’ perceptions and practices on generic medicines: A pilot study from Peninsular Malaysia. 15th International Social Pharmacy Workshop 8-11 July 2008, Queenstown, New Zealand
18. BABAR, Z.U. Medicines Pakistan International: A Pharmaceutical Policy Initiative Connecting People & Ideas. 15th International Social Pharmacy Workshop 8-11 July 2008, Queenstown, New Zealand
19. JAMSHED, S., BABAR, Z.U. Evaluating quality use of generic medicines in Pakistan: An exploratory study. 15th International Social Pharmacy Workshop 8-11 July 2008, Queenstown, New Zealand.
20. BABAR, Z.U. Development of pharmaceutical industry, innovation and public health: Case studies from Malaysia and Pakistan. “Pharmaceutical Policy Conference” 19-21st September 2007. Zeist, the Netherlands.
21. BABAR, Z.U. Medicine use and disease mongering: Challenges for healthcare in Malaysia. Inaugural Conference on Disease Mongering April 11-13, 2006. University of Newcastle, Australia.
Zaheer-Ud-Din Babar, Ph.D. Page 41 of 50 22. VITRY, A., BABAR, Z.U., WILLIAMS, D., GILBERT, A., CHAN, D. Prescribing habits of dispensing doctors in Malaysia – focusing on hypertension. Australasian Pharmaceutical Science Conference, 3-5 December 2006, Adelaide, Australia
23. BABAR, Z.U., IBRAHIM M, IZHAM. M., SINGH, H., BUKHARI, N.I., CREESE A. An evaluation of medicine prices in Malaysia. Sixth Malaysian Pharmacy Scientific Conference, 8-10th September 2006, Kuala Lumpur, Malaysia
24. BABAR, Z.U. Advocacy plan to control medicine prices in Malaysia. Evidence, Advocacy and Policy Workshop on medicine prices. Organized by World Health Organization & Health Action International June 12-15th 2006, Kandy, Sri Lanka.
25. BABAR, Z.U., IBRAHIM M, IZHAM. M. Privatization of General Medical Store (GMS) and the prices of gastrointestinal medicines: An evaluation in Malaysian perspective. MPS Pharmacy Scientific Conference 2005, November 11-13, 2005, Kuala Lumpur, Malaysia.
26. BABAR, Z.U., IBRAHIM M, IZHAM. M. Privatization of General Medical Store (GMS) and the prices of anticancer medicines: An evaluation in Malaysian perspective. The 5th Asian Conference on Clinical Pharmacy. July 23-26, 2005, Penang, Malaysia.
27. BABAR, Z.U, Preliminary findings from a medicine pricing survey. WHO/HAI Post Survey Workshop on Medicine Pricing. May 23-25th,2005, University Sains Malaysia, Penang. Malaysia
28. BABAR, Z.U., IBRAHIM M, IZHAM. M, BUKHARI, N.I. Effect of privatization of General Medical Store (GMS) on prices of anti-infectives in Malaysia. 2nd International Conference on Improving Use of Medicine (ICIUM), March 30-April 2, 2004, Chiang Mai, Thailand.
29. BABAR, Z.U., IBRAHIM M, IZHAM. M, BUKHARI, N.I. Medicine pricing and utilization: The findings of a household survey in Malaysia. MPS Scientific Conference. August 6- 8th 2004, Kuala Lumpur. Malaysia.
30. BABAR, Z.U, BUKHARI, N.I., BAHARI, M.B., YEONG, S.W., EFFENDIE, B. Students’ perception and satisfaction on the knowledge and skills gain in clinical pharmacy clerkship in a teaching hospital in Malaysia. MPS Scientific Conference. August 6-8th 2004, Kuala Lumpur. Malaysia.
31. BABAR, Z.U., IBRAHIM M, IZHAM. M, BUKHARI, N.I. The prices of cardiovascular medicines after privatization of drug distribution system in Malaysia.1st National Health Outcomes Conference “From Research to Practice” July 27-28, 2004, Kuala Lumpur. Malaysia
32. BABAR, Z.U. A preliminary analysis of Malaysian drug pricing scenario. Presented at WHO/HAI workshop on drug pricing, Chulalongkorn University, Bangkok, Thailand. April 5-7, 2004. Zaheer-Ud-Din Babar, Ph.D. Page 42 of 50
33. YEONG, SW., EFFENDIE, B., BUKHARI, N.I., BABAR, Z.U. Public perception of the pharmacy profession. Third Pharmacy Scientific Conference: Pharmacy in the Post- genomic Era, from research to practice, October 10-12th 2003, Kuala Lumpur. Malaysia.
34. BABAR, Z.U., YEONG, SW., CHAPMAN, B.J. A cross-sectional study of consumer perceptions and attitudes towards health care information resources available on the internet. Second Pharmacy Scientific Conference of the Malaysian Pharmaceutical Society. (MPS) October 31st - November 2nd, 2002, Penang, Malaysia.
35. BABAR, Z.U., NOORIZAN, A.A, Yahaya, H. Evaluation of hospital pharmacy services from the customers’ perspective. Second Pharmacy Scientific Conference of the Malaysian Pharmaceutical Society. October 31st - November 2nd, 2002, Penang, Malaysia.
Invited/ Keynote Speaker
1. Pharmacy Practice Research and it’s impact on global health. 2nd International Pharmacy Conference and Exhibition. Islamia University Bahawalpur, Pakistan, 20th Feb 2020. 2. Access to medicines, pharmaceutical policy and patient health outcomes: What’s the future like. 5th Pakistan Pharma Summit. Serena Hotel Islamabad, Pakistan. 19th Feb 2020. 3. Pre-Conference workshop “Understanding global pharmaceutical pricing: Models, case studies and examples. 5th Pakistan Pharma Summit. Serena Hotel Islamabad, Pakistan. 18th Feb 2020. 4. Convergence of “Medicines Access and Use” Dimensions of Policy Research: Examples from a Personal Journey. DRA Lecture, Department of Pharmacy, University of Copenhagen, Denmark, 23rd Jan 2020!
5. Understanding publishing in open access journals”, Qatar University, Doha Qatar 31st October 2019 6. The future of pharmacy services in the UK-an international comparison! Westminster Health Forum 20th November 2019, London, United Kingdom.
7. Improving health and changing lives through pharmacy practice research: Case studies and Examples. Keynote address at Pakistan Pharmacist Association (PPA) Annual Conference, Lahore, Pakistan 27th October 2019 8. Pharmaceutical Policy and Practice Research at the University of Huddersfield, Meeting of WHO Collaborating Centers in the field of Pharmaceutical Policies at Austrian Health Institute, Vienna, Austria, 25th October 2019 9. "Meet the Editor Session". Journal of Pharmaceutical Policy and Practice, Scientific Publishing and Editorship. 4th PPRI conference on pharmaceutical pricing and reimbursement policies kicking off at Palais Niederosterreich, Vienna Austria, 24th October 2019 Zaheer-Ud-Din Babar, Ph.D. Page 43 of 50 10. Getting Involved with the pharmaceutical policy and practice research. Royal Pharmaceutical Society, West Yorkshire Practice Forum, 10th October 2019, Huddersfield, United Kingdom 11. Medicines safety in the broader pharmaceutical policy context: Evidence, impact and the future directions. The 4th International Forum on Drug Safety and Policy, 28th September, Xi'an, China. 12. Pharmacy practice research: what’s the future like. 1st JoPPP Conference on Pharmaceutical Policy and Practice Research, 28th August 2019, Shah Alam, Malaysia 13. Systematic reviews, meta- analysis and publishing high impact research. Pre- Conference workshop, 1st JoPPP Conference on Pharmaceutical Policy and Practice Research, 27th August 2019, Shah Alam, Malaysia 14. Systematic reviews, implications on policy and practice. Workshop at International Islamic University, 26th August 2019, Kuantan, Malaysia 15. Counterfeit medicines: a broader pharmaceutical policy discourse, University College London (UCL) School of Pharmacy, London, December 8, 2018 16. Strengthening Health System through Pharmacy Practice Research, Pakistan Pharmacist Association, Lahore, Pakistan 21st December 2018 17. Methodological issues in Pharmacy Practice Research. Quaid-i-Azam University Islamabad, Pakistan. 18th December 2018 18. Pharmacy Practice Research: Busting the myth: Hamdard University Islamabad, Pakistan. 18th December 2018 19. Pharmacy Practice Research Methods: Theories and application. Shifa University in Islamabad, Pakistan 15th December 2018 20. Responsibility of reproducibility, Better science through better data, Springer Nature Conference, Natural History Museum, London, 14th November 2018. 21. Evidence in Pharmacy Practice” Science in Pharmacy " 13th Pharmacies Congress Lisbon, Portugal. 20th October 2018 22. View from pharmaceutical industry, Medicine Quality and Public Health Conference, Keble College, Oxford University, Oxford 27th September 2018 23. Pharmacy Practice Research: Change, improvement and impact on health system. Management & Sciences University, Kuala Lumpur, Malaysia. 13th July 2018. 24. Pharmacy Practice Research: Evidence, impact and future directions. Thammasat University, Bangkok, Thailand. 11th July 2018. 25. Pharmacy Practice Research: Key differences in low, middle and high-income countries. Pancasila University, Jakarta, Indonesia. 9th July 2018. 26. Pharmacy Practice Research: What needs to be done? International conference on contemporary science and clinical pharmacy, Padang, Indonesia. 5th-6th July 2018. 27. Pharmacy Practice Research: theories, skills, analysis and application. Akhtar Saeed College of Pharmaceutical Sciences, Lahore, Pakistan. 23rd November 2017. 28. Pharmacy Practice Research: Shaping the future. College of Pharmacy, University of the Punjab, Lahore, Pakistan, 22nd Nov 2017. 29. What needs to be done to improve pharmacy practice research. 2nd International Conference on Recent advances in pharmaceutical sciences. Riphah International University, Margalla Hotel, Islamabad, Pakistan. 15th-16th Nov 2017. 30. Pharmacy Practice Research: Challenges, opportunities, theories. Pakistan Pharmacists Association (PPA), PPA House, Lahore, Pakistan 20th Nov 2017 31. Medicines, money and you: Challenges in the 21st Century Public. lecture organised by School of Applied Sciences, University of Huddersfield, United Kingdom 18th October 2017 Zaheer-Ud-Din Babar, Ph.D. Page 44 of 50 32. Pharmaceutical policy economics and healthcare system. Second British Council, UK Egypt Pharmacoeconomics Workshop, 21st July 2017 Novotel Brentford, London 33. Advancing medicines optimisation and health outcomes through stable health systems. Department of Pharmacy, School of Applied Sciences, University of Huddersfield, 16th September 2016, Huddersfield, United Kingdom 34. Pharmaceutical Policies in Australia and New Zealand. The 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis, 12th -13th October 2015, Vienna Austria 35. Latest trends in pharmaceutical pricing policies and gaps in evidence. The 2nd Meeting on Access to Medicines under Universal Health Coverage in the Asia Pacific Region 17-18 September 2015, Seoul, Republic of Korea 36. The future of pharmacy practice research. The 1st International Conference on “Recent Innovations in Pharmaceutical Sciences, 3-5th March 2015. Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan 37. Identifying priority medicines policy issues for New Zealand. Lecture delivered at Department of Population Medicine, Harvard Medical School Boston on 16th April 2014. 38. Publishing your scientific research. Lecture delivered at Department of Population Medicine, Harvard Medical School Boston,10th April 2014. 39. How to publish your research? Lecture delivered at Boston University School of Public Health, Boston 9th April 2014. 40. Community Pharmacy Practice in Low and High-Income Countries. Lecture delivered at Boston University School of Public Health, Boston 9th April 2014. 41. Community Pharmacy Practice in Low and High-Income Countries. Lecture delivered at Monash University Malaysia Campus, 3rd Sep 2014, Kuala Lumpur, Malaysia
42. Publish or perish, publishing scientific research. Workshop conducted at Faculty of Pharmacy, International Islamic University Kuantan Malaysia 4-7th Sep 2014.
43. Publishing scientific research. Health Action International Amsterdam, Netherlands, 16th Sep 2014.
44. Pharmaceutical policies in NZ. Gesundheit Österreich GmbH (Austrian Health Institute) 22nd Sept 2014, Vienna Austria.
45. Medicines policy in New Zealand. Lecture delivered at School of Pharmacy, Reading University, Reading UK. 24th Sep 2014 46. Medicines policy issues in New Zealand. Lecture delivered at School of Pharmacy, Kingston University, London, UK. 26th Sep 2014 47. Medicines policy and funding issues in New Zealand. Lecture delivered at School of Pharmacy, Universiti Sains Malaysia, Penang, Malaysia. 30th Sep 2014 48. Publishing scientific research. Universiti Institute Teknologi Mara (UiTM), Pulau Penang 30th Sep 2014.
49. I have delivered a lecture entitled “The Trans Pacific Partnership (TPP) Agreement and Access to Medicines: Public health implications and advocacy” at the Auckland Branch PHA meeting on 21st Nov 2013. 50. Trans Pacific Partnership Agreement and Access to Medicines in New Zealand.Public Health Physicians Meeting, Greenlane Clinical Centre, Auckland 26th May 2011 Zaheer-Ud-Din Babar, Ph.D. Page 45 of 50 51. Medicines policy, pharmacists and healthcare systems: Opportunities, Challenges and the ideas for action. 27th December 2011. College of Pharmacy, University of the Punjab, Lahore, Pakistan 52. Evaluating drug prices in Malaysia. Pharma Tell Seminar, School of Pharmacy, The University of Auckland, 23rd July 2007, Auckland, New Zealand. 53. “Pharmaceutical Policy & Healthcare System: Emerging Issues in Developing Countries”. Delivered at the Aga Khan University (Medical College), 23rd April, Karachi, Pakistan. 54. An Introduction to Pharmaceutical Pricing in Malaysia” Delivered at the Applied Health Economics Course organized by Institute of Health Management, 4th April, Kuala Lumpur, Malaysia. 55. “How to Evaluate Drug Prices in Malaysia?” Introductory Health Economics Course (Part II) organized by Institute of Health Management, 17th April, Kuala Lumpur, Malaysia. 56. “Development of the Role of Community Pharmacist in Smoking Cessation Programmes”. Delivered at the Continuing Professional Development (CPD) Seminar organized by Malaysian Pharmaceutical Society and Universiti Institute Teknologi Mara (UiTM). 31st March, 2007, Penang, Malaysia. 57. Equitable Access to Medicine for Malaysians: A Way Forward through a Medicine Pricing Policy, Seminar Organized by School of Pharmaceutical Sciences & Women’s Development Research Centre, Universiti Sains Malaysia, 27th March, 2007, Penang, Malaysia 58. “Hypertension: A Silent Killer”, Public talk delivered on The 2nd Annual Public Health Campaign, Organized by University College Sedaya International (UCSI), Sunway Pyramid, Oceania Square. 16-18 May 2003, Kuala Lumpur.
Research Grants Received
Granting Title Role Amount Term of Grant Agency Start End date date COVID-19 pump-priming £2,500 May July internal URF fund 2020 2020 2020 : Experiences and (in GBP) University of expectations of community Principal Huddersfield, pharmacist dealing with Investigator United Kingdom COVID-19: A qualitative study
Zaheer-Ud-Din Babar, Ph.D. Page 46 of 50 GCRF Sandpit £7,500 Feb July Project: Development of 2018 2018 University of Sustainable Health Systems (in GBP) Principal Huddersfield, Through Investigating Investigator United Kingdom Medicine Prices and Affordability
£110,270 April March University of Medicines management and Chief 2017 2019 Huddersfield, cost effectiveness in United Investigator (in GBP) United Kingdom Kingdom (URF Funding)
Investigating medicines $250,000 March March pricing, availability and Lead 2016 2018 World Bank, affordability in Bangladesh Consultant to Washington DC using WHO/HAI the study methodology International International remuneration 75,000 € June Dec Co- Pharmaceutical models of hospital and 2013 2015 investigator Federation (FIP) community pharmacies The University of Priority Medicines Policy Principal 25,000 April April Auckland Issues for New Zealand Investigator NZ$ 2012 2014 International Evaluating medicines prices, Principal 32,000 April August Union Against affordability and availability Investigator NZ$ 2011 2011 Tuberculosis and of essential asthma Lung Disease, medicines in 52 low and Paris , France middle-income countries New Zealand Access to medicines in NZ: Principal 3500 NZ$ 2010 2012 Pharmacy and Comparing the health and Investigator Education economic indicators with the
Research United Kingdom, Australia Foundation and Canada (NZPERF) Faculty Research Evaluating general Principal 46,350 2009 2011 Development practitioners’ and Investigator NZ$ Fund (FRDF) community pharmacists’ Co investigators University of opinions on issues A/P Janie Auckland, New concerning access to Sheridan Zealand medicines and generic medicines in New Zealand New Zealand General Practitioners’ Principal 4218 NZ$ 2009 2010 Pharmacy and perceptions of issues Investigator Education concerning access to Co investigators Research medicines in New Zealand A/P Janie Foundation Sheridan, Ms (NZPERF) Lynne Bye
Zaheer-Ud-Din Babar, Ph.D. Page 47 of 50 Co- investigator Principal Sustainability of Investigator FRST (TIF) pharmaceutical policy and 93,000 Michelle Technology drug development industry in NZ$ Lockhart, A/P Industry New Zealand Nov Oct Sanjay Garg Fellowship, NZ 2008 2011 Effect of Privatization of Principal Malaysian Drug Distribution 2000 Investigator UCSI University, System on the Prices of MYR$ Malaysia Medicines in Malaysia 2005 2006 Health Action International Measuring medicine prices, (HAI) availability affordability in Principal Netherlands Malaysia by using WHO/HAI Investigator Methodology 6000 US$ 2004 2005
Professional Organizations 2017- Commonwealth Pharmacist Association (CPA) 2011- 2015 ISPOR 2009 - till now Member World Association of Medical Editors (WAME) 2010-2013 Associate Member of Pharmaceutical Society of New Zealand 2001-2005 Associate Member of Malaysian Pharmaceutical Society 2005-2006 Member of International Health Economics Association (IHEA) 2002-2003 European Society of Clinical Pharmacy
Meetings Attended as a Resource Person (By Invitation) 1. Meeting of WHO Collaborating Centres in the field of pharmaceutical policies, 25th October 2019.Hosted by the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. 2. BioMed Central and Springer Open’s Editors Conference, London 28th June 2018
3. Encyclopedia of Pharmacy Practice and Clinical Pharmacy: content meeting. Elsevier, Kidlington Oxford, United Kingdom, March 6-7th 2017 4. BioMed Central and Springer Open’s Editors Conference, London 9th-10th May 2017 5. Pharmacy Practice Research Retreat, 2nd May 2017 Bagden Hall Hotel, Huddersfield 6. BMC Editors Conference, Doha Qatar, 21st April-26th April 2014 7. Meeting of WHO Collaborating Centres in the field of pharmaceutical policies, October 14th 2015.Hosted by the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. 8. Economic modeling of likely impact of stronger intellectual property protection on medicine prices. Workshop organized by World Health Organization & Ministry of Health, Malaysia. 9-12th July 2006, Kuala Lumpur, Malaysia. 9. COMSATS Institute of information Technology, Abbottabad, Pakistan President Programme for Highly Qualified Overseas Pakistanis. Dec 2013. The programme was sponsored by National Talent Pool, Ministry of Training Standards and Higher Education, Government of Pakistan, Islamabad Pakistan. Zaheer-Ud-Din Babar, Ph.D. Page 48 of 50 10. Project Meeting on the Research on the use of Traditional and Complementary Medicines including Nutraceuticals Organized by Consumer International, Kuala Lumpur, Malaysia. 27-29 April 2004. 11. Project Meeting on Global WHO/HAI Project on Medicine Pricing. 28th November-3rd December 2006, World Health Organization’s Eastern Regional Mediterranean Regional Office, Cairo, Egypt.
12. Malaysian Medicine Policy Conference, Organized by Ministry of Health Malaysia and World health organization (WHO). March 17- 18, 2003. Kuala Lumpur.
13. Consumer Medicines Surveillance Seminar 2007. Pilot Project on Involving Consumers in Medicines Surveillance. 9th January 2007, Kuala Lumpur, Malaysia.
14. Evidence, Advocacy and Policy Workshop on medicine prices. Organized by World Health Organization & Health Action International June 12-15th 2006, Kandy, Sri Lanka.
15. Regional Seminar on Healthcare Financing & Traditional Medicines. Organized by Health Action International-Asia Pacific. 15-17th April 2004, Penang, Malaysia Workshop Coordinator
1. Babar ZU, Ewen M. Access to Drugs and Pharmaceutical Pricing: Methodological Issues in Medicine Pricing Research.15th International Social Pharmacy Workshop 8- 11th July 2008, Queenstown, New Zealand.
2. Conducting medicines pricing survey in Bangladesh. workshop organised by International Centre for Diarrheal Disease Research (Iccdr,b) and World Bank Country Office, 5th-6th October 2016, Dhaka, Bangladesh.
3. Pharmacy Practice Research Methods Workshop. Lahore Pharmacy College and Lahore College for Women University, 28th May 2016, Lahore, Pakistan.
Editorial Board /Editorial Responsibilities
Editor-in-Chief JoPPP Editorial Board Member Research in Social and Administrative Pharmacy (RSAP) British Journal of Pharmacy Science, Technology and Development Join Editor Pharmacy Focus - a biannual magazine of School of Pharmacy, University of Auckland (2008-2010) Reviewer Australian Prescriber, American Journal of Pharmaceutical Education, BMC Public Health, Bulletin of the World Health Organization, Globalization and Health, Health Policy, Health Affairs, Journal of Pakistan Medical Association (JPMA), Journal of Primary Health Care, Medical Education, Pharmacy World & Science, PLoS Medicine, Pharmacy Practice, Tropical Medicine & International Health, BMC Health Services Research, BMC Zaheer-Ud-Din Babar, Ph.D. Page 49 of 50 Medicine, Lancet
Conference & Seminar Participation
1. 20th ISPOR Annual European Congress, 5th-7th November 2018, Glasgow, Scotland 2. Editorial Board Meeting, Science, Technology and Development. Pakistan Council for Science and Technology, Islamabad Pakistan.17th November, 2017 3. Welsh Medicines Research Symposium, Faenol Fawr, Bodelwyddan 18th July 2017 4. Health Services and Pharmacy Practice Research Conference at the University of Nottingham, April 10-11, 2017 5. Economic modelling for product reimbursement, ISPOR New Zealand Chapter, Auckland City Hospital, 31st October 2014. 6. Industry influence in healthcare and research: Does it matter? Organised by Cochrane New Zealand. University of Auckland 24th November 2014. 7. Integrated Care: The key to reforming our health systems, University of Auckland 28th July 2014. 8. 1st Annual State of Global Health Symposium, Harvard School of Public Health Boston, MA 15th April 2014http://www.hsph.harvard.edu/global-health-and- population/events/1st-annual-state-of-global-health-symposium/ 9. Attended ISAAC 20 Year Anniversary Symposium, Asthma, Eczema, Rhinitis and the Environment, 27th Jan 2011, University of Auckland 10. PHARMAC Forum 11th October 2009. 11. Malaysian Pharmaceutical Conferences in 2002, 2003, 2004, 2005, 2006. 12. 14th Malaysian Conference on Pharmacology and Physiology. May 6-9, 1999. Penang. 13. “International Pharmacy Practice” Organized by Malaysian Pharmaceutical Society (MPS) in conjunction with the FIP-WPPF, July 12-13 2003, Kuala Lumpur. 14. Respirology Pharmacy Conference “Updates in Respiratory Pharmaceutical Care” Organized by Malaysian Pharmaceutical Society (MPS) & Selangor State Health Department. May 9-11 2003, Kuala Lumpur. 15. “International Clinical Pharmacy Symposium”, Jointly Organized by International Medical University and University of Strathclyde. July 22–23, 2002. Kuala Lumpur. 16. CNS - related Illnesses: “The Current Trend of Treatment & Management”. Organized by: Malaysian Pharmaceutical Society & Janssen-Cilag. July 4th 2002, Kuala Lumpur. 17. Member of the Organizing Committee of the Joint Cardiovascular Rehabilitation Conference and Counseling Workshop, University Sains Malaysia. May 6-10, 1999, Penang. 18. International Pharmaceutical Conference and Exhibition Organized by Pakistan Pharmacist Association (PPA), March 20-23, 1998. Lahore, Pakistan. Newspaper & Internet Articles/Radio Interviews
1. Article in Urdu on Buying Medicineshttp://nuktanazar.sujag.org/pharmacist-
medicine-doctor-pakistan 29th June 2017
2. Dr Zaheer Babar, Radio Interview. 4th Dec 2015. Study finds wildly different cancer drug Zaheer-Ud-Din Babar, Ph.D. Page 50 of 50 prices.http://www.radionz.co.nz/national/programmes/ninetonoon/audio/20178 1423/study-finds-wildly-different-cancer-drug-prices 3. Dr. Zaheer Babar on Pharmaceutical Policy. Radio Interview, Auckland. 21st August 2012.http://www.95bfm.com/default,207010.sm 4. Dr Zaheer Babar , Equitable access to medicines. Radio Interview, Auckland. 12th June 2014 http://www.95bfm.co.nz/default,216227.sm 5. Increasing prescription charge threatens access to medicine, Dominion Post, Wellington. 29th June 2012 http://www.stuff.co.nz/dominion- post/comment/7188592/Increasing-prescription-charge-threatens-access-to- medicine 6. Helping smokers to stay stopped, Article Published in Pharmacy Today, Nov 2008 New Zealand. 7. Rationale Behind drug pricing. Dawn 26th Feb, 2008 http://www.dawn.com/2008/02/26/letted.htm#2 8. Counterfeit Drugs in Pakistan. Implications for Public Health and the Pharmaceutical Industry. Newsletter of the World Health Forum, April 2006. Available at: http://www.worldhealthforum.us/newsletter/issue1/pakistan.htm 9. Pakistan’s Pharmaceutical Industry. Dawn 17th June 2005. Available at: http://www.dawn.com/2005/06/17/letted.htm#1 10. Pharm.D Programme. Dawn 1st March 2004. Available at: http://www.dawn.com/2004/03/01/letted.htm#3